<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html id="nojs" xmlns="http://www.w3.org/1999/xhtml" xmlns:m="http://www.w3.org/1998/Math/MathML" xmlns:og="http://ogp.me/ns#" xml:lang="en-GB" lang="en-GB" xmlns:wb=“http://open.weibo.com/wb”>

<head>

   
  
      
  
                  
  
                  
  
            
  
            
            
    <title>Trials | Full text | Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial</title>
<link rel="shortcut icon" type="image/x-icon" href="/images/icon/10096/favicon.ico" />
<link rel="apple-touch-icon" sizes="72x72" href="/sites/10096/images/70.gif" />
<meta http-equiv="X-UA-Compatible" content="IE=7" />


                
    
		
		
		
		
<!-- <?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:cc="http://web.resource.org/cc/" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
<cc:Work rdf:about="http://www.trialsjournal.com/content/16/1/39">
<cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
</cc:Work>
<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
<cc:permits rdf:resource="http://web.resource.org/cc/Reproduction"/>
<cc:permits rdf:resource="http://web.resource.org/cc/Distribution"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Notice"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Attribution"/>
<cc:permits rdf:resource="http://web.resource.org/cc/DerivativeWorks"/>
</cc:License>
<item rdf:about="http://www.trialsjournal.com/content/16/1/39">
<title>Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial</title>
<dc:title>Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial</dc:title>
<dc:creator>Nichol, Alistair</dc:creator>
<dc:creator>French, Craig</dc:creator>
<dc:creator>Little, Lorraine</dc:creator>
<dc:creator>Presneill, Jeffrey</dc:creator>
<dc:creator>Cooper, D J</dc:creator>
<dc:creator>Haddad, Samir</dc:creator>
<dc:creator>Duranteau, Jacques</dc:creator>
<dc:creator>Huet, Olivier</dc:creator>
<dc:creator>Skrifvars, Markus</dc:creator>
<dc:creator>Arabi, Yaseen</dc:creator>
<dc:creator>Bellomo, Rinaldo</dc:creator>
<dc:creator>On behalf of the EPO-TBI Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group</dc:creator>
<dc:identifier>info:doi/10.1186/s13063-014-0528-6</dc:identifier>
<dc:source>Trials 2015, 16:39</dc:source>
<dc:date>2015-02-08</dc:date>

<prism:publicationName>Trials</prism:publicationName>
<prism:publicationDate>2015-02-08</prism:publicationDate>
<prism:volume>16</prism:volume>
<prism:number>1</prism:number>
<prism:section>Study protocol</prism:section>
<prism:startingPage>39</prism:startingPage>
<prism:copyright>2015 Nichol et al.; licensee BioMed Central.</prism:copyright>
</item>
</rdf:RDF>
 -->
 
 
<meta name="citation_journal_title" content="Trials" />
<meta name="citation_publisher" content="BioMed Central Ltd" />


<meta name="citation_author" content="Alistair Nichol" />
<meta name="citation_author_institution" content="Department of Anaesthesia and Intensive Care Medicine, St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland" />
<meta name="citation_author_institution" content="School of Medicine and Medical Sciences, University College Dublin, Elm Park, Dublin 4, Ireland" />
<meta name="citation_author_institution" content="Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne 3004, Australia" />
<meta name="citation_author_institution" content="Department of Intensive Care Medicine, The Alfred, Commercial Road, Melbourne 3004, Australia" />
<meta name="citation_author" content="Craig French" />
<meta name="citation_author_institution" content="Department of Intensive Care, Western Health, Gordon Street, Footscray 3011, Australia" />
<meta name="citation_author_institution" content="Department of Medicine North West Academic Centre, The University of Melbourne, Grattan Street, Parkville 3052, Australia" />
<meta name="citation_author" content="Lorraine Little" />
<meta name="citation_author_institution" content="Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne 3004, Australia" />
<meta name="citation_author" content="Jeffrey Presneill" />
<meta name="citation_author_institution" content="Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne 3004, Australia" />
<meta name="citation_author_institution" content="Department of Intensive Care, Mater Health Services, Raymond Terrace, South Brisbane 4101, Australia" />
<meta name="citation_author" content="D J Cooper" />
<meta name="citation_author_institution" content="Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne 3004, Australia" />
<meta name="citation_author_institution" content="Department of Intensive Care Medicine, The Alfred, Commercial Road, Melbourne 3004, Australia" />
<meta name="citation_author" content="Samir Haddad" />
<meta name="citation_author_institution" content="Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne 3004, Australia" />
<meta name="citation_author_institution" content="Department of Intensive Care, King Abdulaziz Medical City, Riyadh 11426, Kingdom of Saudi Arabia" />
<meta name="citation_author" content="Jacques Duranteau" />
<meta name="citation_author_institution" content="Service d’Anesthésie-Réanimation, Hôpitaux universitaires Paris Sud, Assistance Publique des Hôpitaux de Paris, Hôpital de Bicêtre, 78, rue du Général Leclerc, Le Kremlin Bicêtre, 94275, France" />
<meta name="citation_author_institution" content="Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne 3004, Australia" />
<meta name="citation_author" content="Olivier Huet" />
<meta name="citation_author_institution" content="Department of Anesthesiology and Intensive Care Medicine, Centre Hospitalier Universitaire La Cavale Blanche Université de Bretagne Ouest, Brest Cedex, 29609, France" />
<meta name="citation_author" content="Markus Skrifvars" />
<meta name="citation_author_institution" content="Department of Anaesthesiology and Intensive Care Medicine, Helsinki University Hospital, Helsinki, FIN-00029, Finland" />
<meta name="citation_author" content="Yaseen Arabi" />
<meta name="citation_author_institution" content="Intensive Care Department, College of Medicine King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh 11426, Kingdom of Saudi Arabia" />
<meta name="citation_author_institution" content="Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne 3004, Australia" />
<meta name="citation_author" content="Rinaldo Bellomo" />
<meta name="citation_author_institution" content="Department of Intensive Care, Austin Health, Studley Road, Heidelberg 3084, Australia" />
<meta name="citation_author_institution" content="Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne 3004, Australia" />
<meta name="citation_author_institution" content="Department of Medicine North West Academic Centre, The University of Melbourne, Grattan Street, Parkville 3052, Australia" />
<meta name="citation_author" content="$author.firstName $author.lastName" />


<meta name="citation_issn" content="1745-6215" />
<meta name="citation_title" content="Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial" />
<meta name="citation_volume" content="16" />
<meta name="citation_issue" content="1" />
<meta name="citation_date" content="2015-02-08" />
<meta name="citation_firstpage" content="39" />
<meta name="citation_doi" content="10.1186/s13063-014-0528-6" />
<meta name="citation_pdf_url" content="http://www.trialsjournal.com/content/pdf/s13063-014-0528-6.pdf" />
<link rel="alternate" type="application/pdf" title="PDF" href="http://www.trialsjournal.com/content/pdf/s13063-014-0528-6.pdf" />
<meta name="title" content="Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial" />
<meta name="description" content="Traumatic brain injury is a leading cause of death and disability worldwide. Laboratory and clinical studies demonstrate a possible beneficial effect of erythropoietin in improving outcomes in the traumatic brain injury cohort. However, there are concerns regarding the association of erythropoietin and thrombosis in the critically ill. A large-scale, multi-centre, blinded, parallel-group, placebo-controlled, randomised trial is currently underway to address this hypothesis." />

<meta name="dc.title" content="Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial" />
<meta name="dc.creator" content="Nichol, Alistair" />
<meta name="dc.creator" content="French, Craig" />
<meta name="dc.creator" content="Little, Lorraine" />
<meta name="dc.creator" content="Presneill, Jeffrey" />
<meta name="dc.creator" content="Cooper, D J" />
<meta name="dc.creator" content="Haddad, Samir" />
<meta name="dc.creator" content="Duranteau, Jacques" />
<meta name="dc.creator" content="Huet, Olivier" />
<meta name="dc.creator" content="Skrifvars, Markus" />
<meta name="dc.creator" content="Arabi, Yaseen" />
<meta name="dc.creator" content="Bellomo, Rinaldo" />
<meta name="dc.creator" content="On behalf of the EPO-TBI Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group" />
<meta name="dc.description" content="Traumatic brain injury is a leading cause of death and disability worldwide. Laboratory and clinical studies demonstrate a possible beneficial effect of erythropoietin in improving outcomes in the traumatic brain injury cohort. However, there are concerns regarding the association of erythropoietin and thrombosis in the critically ill. A large-scale, multi-centre, blinded, parallel-group, placebo-controlled, randomised trial is currently underway to address this hypothesis." />
<meta name="dc.source" content="Trials 2015 16:39" />
<meta name="dc.format" content="text/html" />
<meta name="dc.publisher" content="BioMed Central Ltd" />
<meta name="dc.date" content="2015-02-08" />
<meta name="dc.type" content="Study protocol" />
<meta name="dc.identifier" content="10.1186/s13063-014-0528-6" />
<meta name="dc.language" content="en" />
<meta name="dc.copyright" content="2015 Nichol et al.; licensee BioMed Central." />
<meta name="dc.rights" content="http://creativecommons.org/licenses/by/2.0/" />
<meta name="dc.rightsAgent" content="reprints@biomedcentral.com" />

<meta name="prism.issn" content="1745-6215" />
<meta name="prism.publicationName" content="Trials" />
<meta name="prism.publicationDate" content="2015-02-08" />
<meta name="prism.volume" content="16" />
<meta name="prism.number" content="1" />
<meta name="prism.section" content="Study protocol" />
<meta name="prism.startingPage" content="39" />
<meta name="prism.copyright" content="2015 Nichol et al.; licensee BioMed Central." />
<meta name="prism.rightsAgent" content="reprints@biomedcentral.com" />


        <meta name="citation_abstract_html_url" content="http://www.trialsjournal.com/content/16/1/39/abstract" />
            <meta name="citation_fulltext_html_url" content="http://www.trialsjournal.com/content/16/1/39" />
            <link rel='alternate' type='text/xml' title='XML version' href='http://www.trialsjournal.com/content/download/xml/s13063-014-0528-6.xml' />
            <link rel="image_src" href="http://www.trialsjournal.com/content/figures/s13063-014-0528-6-toc.gif" />
    
     <link rel="section" href="http://trialsjournal.com/content/download/supplementary/s13063-014-0528-6-s1.pdf" title="Additional file 1:" />
    
    
                    
    

<script type="text/javascript">
// must run before css
document.documentElement.id = "js";
</script>



						
   
  
      
  
                  
  
                  
  
            
  
            
            



						
        <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery-1.8.2.min-0.js"></script>

	                <link rel="stylesheet" type="text/css" href="/css/main-0.css" media="screen, print"/>
    
                <link rel="stylesheet" type="text/css" href="/css/plugins-0.css" media="screen, print"/>
    



    

			                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/articles-0.css" media="screen, print"/>
    	

    

    <link rel="stylesheet" type="text/css" href="/css/themes/10096.css" media="screen, print"/>


                <link rel="stylesheet" type="text/css" href="/css/media/print-0.css" media="print"/>
    



<!--[if IE]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie-0.css"/>
    <![endif]-->

<!--[if IE 7]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie7-0.css"/>
    <![endif]-->
			
<script type="text/javascript">
    //configuration
    OAS_url = '//oas.biomedcentral.com/RealMedia/ads/';

	// control of advert's position on page [AMC]
    
    	
	
    OAS_sitepage = "trialsjournal.com/article/10.1186/s13063/014/0528/6";
    	
		OAS_listpos = 'Top,x96,Right3';
	
	
			
		OAS_query = '';
		
	

    OAS_target = '_top';
    //end of configuration
    OAS_version = 10;
    OAS_rn = '001234567890'; OAS_rns = '1234567890';
    OAS_rn = new String (Math.random()); OAS_rns = OAS_rn.substring (2, 11);
    function OAS_NORMAL(pos) {
		document.write('<a href="' + OAS_url + 'click_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" target="' + OAS_target + '">');
		document.write('<img src="' + OAS_url + 'adstream_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" border="0"/></a>');
    }
    
	function refererTerms(referer) {

	if(referer.match("q=") != null) {
		referer = referer.split("q=");
		referer = referer[1].split("&");
		referer = referer[0];
	} else {
		referer = referer;
	}

		if(referer.match("%20") != null && referer.match("%20").length >= 1) {
			referer =  referer.replace(/%20/gi,"+");
			return referer;
		} else { 
			return referer; 
		}
	}
 </script>


 <script type="text/javascript">
	// Set the version of JavaScript to 10 for a Browser 'Mozilla/3' on webTV 
    OAS_version = 11;
    if ((navigator.userAgent.indexOf('Mozilla/3') != -1) || (navigator.userAgent.indexOf('Mozilla/4.0 WebTV') != -1)) {
     OAS_version = 10; }
    if (OAS_version >= 11) {
    document.write('<scr' + 'ipt type="text/javascript" src="' + OAS_url + 'adstream_mjx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '?' + OAS_query + '"><\/script>'); }
</script>
	
<script type="text/javascript">
    document.write('');
	
    function OAS_AD(pos) {
        if (OAS_version >= 11)
         OAS_RICH(pos);
        else
         OAS_NORMAL(pos);
    }
 </script>
	





<script type="text/javascript">
    jsonLoaders = function(){
        var _loaders = [];
        return {
            register: function(config){
                config.prefix = config.prefix || '/webapi/1.0/blogs/';
                config.feedLength = config.feedLength || 3;

                _loaders.push(config);
            },
            list: function(){return _loaders}
        };
    }();

    function totext() {
	    document.write('<a href="javascript:returnToText();">Return to text</a>');
    }

    function retrieve_doi(){
        var metas = document.getElementsByTagName('meta');
        var i;
        for (i = 0; i < metas.length; i++)
            if (metas[i].getAttribute('name') == "citation_doi")
                break;
        var citation_doi = metas[i].getAttribute('content');
        return citation_doi;
    }

</script>





    <script src="http://tjs.sjs.sinajs.cn/open/api/js/wb.js" type="text/javascript" charset="utf-8"></script>
        <link title="Latest articles" rel="alternate" href="http://www.trialsjournal.com/latest/rss" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Most viewed" rel="alternate" href="http://www.trialsjournal.com/mostviewed/rss/" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Latest comments" rel="alternate" href="http://www.trialsjournal.com/latestcomments/rss" type="application/rss+xml" exposeToHeader="true"/>
    


	<script type="text/javascript">
	var _gaq = _gaq || [];
	_gaq.push(['_setAccount', 'UA-9663741-5']);
	_gaq.push(['_gat._anonymizeIp']);
	_gaq.push(['_setLocalRemoteServerMode']);
	
	/*for cross domain tracking*/
	//_gaq.push(['_setAllowLinker', true]);
    //_gaq.push(['_setDomainName', 'trialsjournal.com']); //this journal's domain
	/**/
	
		_gaq.push(['_trackPageview']); 

	(function() {
		var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
		ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
		var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);

		//var iframe = document.getElementById('casesdb-search-widget');
		//if(iframe !== null) {
		//	var pageTracker = _gat._getTrackerByName();
		//	iframe.src = pageTracker._getLinkerUrl('http://www.casesdatabase.com/');
		//}
	})();
	</script>

	
        </head>


<body class=" theme    ">


        



   
  
      
  
                  
  
                  
  
            
  
            
            

    

<div id="oas-campaign" style="display:none">trialsjournal.com/article/10.1186/s13063/014/0528/6</div>
<div id="oas-positions" style="display:none">Bottom,Top</div>

<div id="branding" role="banner">
                			
		<dl class="google-ad wide ">
	<dt class="hide">
					<a class="banner-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising"></a>
				
			</dt>
		<dd>

		<!-- OAS AD 'Top' begin -->
		<script type="text/javascript">
		OAS_AD('Top');

		</script>
		<!-- OAS AD 'Top' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad wide noscript">  
    <dt class="hide"></dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/014/0528/6/15213421437@Top?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/014/0528/6/14224423617@Top?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
			            <div class="sup-panel-outer">
        <div class="sup-panel-inner">

            <style>
  #nojs li.greeting, #nojs li#loginLink {display:none;}
</style>


<ul id="login" class="login">

    <noscript><li><a href="/log"><img class="greeting" src="/images/log.gif"/></a></li></noscript>
    
    <li id="welcome"><span id="username"></span></li>

    <li id="loginLink"><a href=""></a></li>
    
    
</ul>

<script>

function login() {

/* cookie getter/setter */
var allCookies = {
  getItem: function (sKey) {
    if (!sKey || !this.hasItem(sKey)) { return null; }
    return unescape(document.cookie.replace(new RegExp("(?:^|.*;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=\\s*((?:[^;](?!;))*[^;]?).*"), "$1"));
  },
  setItem: function (sKey, sValue, vEnd, sPath, sDomain, bSecure) {
    if (!sKey || /^(?:expires|max\-age|path|domain|secure)$/i.test(sKey)) { return; }
    var sExpires = "";
    if (vEnd) {
      switch (vEnd.constructor) {
        case Number:
          sExpires = vEnd === Infinity ? "; expires=Tue, 19 Jan 2038 03:14:07 GMT" : "; max-age=" + vEnd;
          break;
        case String:
          sExpires = "; expires=" + vEnd;
          break;
        case Date:
          sExpires = "; expires=" + vEnd.toGMTString();
          break;
      }
    }
    document.cookie = escape(sKey) + "=" + escape(sValue) + sExpires + (sDomain ? "; domain=" + sDomain : "") + (sPath ? "; path=" + sPath : "") + (bSecure ? "; secure" : "");
  },
  removeItem: function (sKey, sPath) {
    if (!sKey || !this.hasItem(sKey)) { return; }
    document.cookie = escape(sKey) + "=; expires=Thu, 01 Jan 1970 00:00:00 GMT" + (sPath ? "; path=" + sPath : "");
  },
  hasItem: function (sKey) {
    return (new RegExp("(?:^|;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=")).test(document.cookie);
  },
  keys: /* optional method: you can safely remove it! */ function () {
    var aKeys = document.cookie.replace(/((?:^|\s*;)[^\=]+)(?=;|$)|^\s*|\s*(?:\=[^;]*)?(?:\1|$)/g, "").split(/\s*(?:\=[^;]*)?;\s*/);
    for (var nIdx = 0; nIdx < aKeys.length; nIdx++) { aKeys[nIdx] = unescape(aKeys[nIdx]); }
    return aKeys;
  }
};

// converts cookie into js object
function parseCookie(cookie) {

    cookie = cookie.split("&");
    var obj = {};

    for(var i = 0; i < cookie.length; i++) {

        var c = cookie[i].split("=");

        c[0] = c[0].replace('"','');
        
        obj[c[0]] = c[1];

    }
    return obj;
}

    var cookie = allCookies.getItem("bmccookie");

    var obj = (cookie != null) ? parseCookie(cookie) : {};
    

        var welcome = "";

        if(obj.hasOwnProperty("fname")) {

            // insert user welcome
            welcome = obj.fname.replace(/\+/g, " ") + " " + obj['lname'].replace(/\+/g," ");

            if(jQuery("#welcome").length > 0) {
              jQuery("#welcome").prepend("<strong>Welcome</strong> ");
              jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log off");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logoff");

            window.bmcloggedon = true;


        } else if(obj.hasOwnProperty("institution_name")) {

            // insert institution name
            welcome = obj["institution_name"].replace(/\+/g," ");
            
            if(jQuery("#welcome").length > 0) { 
                jQuery("#welcome").prepend("<strong>Welcome</strong> ");
                jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;


        } else {
            jQuery("#welcome").innerHTML = "";
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;

        }


        // if athens login cookie doesn't exist and the athens login link is visible then remove it.
        if(allCookies.hasItem("athens") != true && document.getElementById("loginAthensLink") != null) {
          jQuery("#loginAthensLink").hide();
        }

}

login();


</script>

            <ul class="nav-sup">

    
        <li id="BMC" class="current">
            <a href="http://www.biomedcentral.com/"><span class="img-title">&nbsp;</span>
            <span class="text-title">BioMed Central</span></a>
        </li>
		
        		<li><a href="http://www.biomedcentral.com/journals"><span>Journals</span></a></li>
		
								<li>
				<a href="http://www.biomedcentral.com/gateways"><span>Gateways</span></a>
			</li>
					    	
</ul>
        </div>
    </div>
    <div class="branding-inner">

        

    
<style>
.survey {
	margin: 10px 0;
}
.survey, .survey .survey-sentence {
	font-size: 13px;
}
.survey-button a, .survey-button a:active, .survey-button a:visited, .survey-button a:hover  {
    color: #FFFFFF;
    text-decoration: none;
}
.survey-button {
	background-color: #FFA500;
    border-radius: 5px;
    color: #FFFFFF;
    font-weight: bold;
    font-size: 13px;
    font-weight: bold;
    padding: 5px 13px;
    background: #ef8142; /* Old browsers */
	background: -moz-linear-gradient(top,  #ef8142 0%, #ef8142 50%, #a64510 100%, #a64510 100%); /* FF3.6+ */
	background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,#ef8142), color-stop(50%,#ef8142), color-stop(100%,#a64510), color-stop(100%,#a64510)); /* Chrome,Safari4+ */
	background: -webkit-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Chrome10+,Safari5.1+ */
	background: -o-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Opera 11.10+ */
	background: -ms-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* IE10+ */
	background: linear-gradient(to bottom,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* W3C */
	filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ef8142', endColorstr='#a64510',GradientType=0 ); /* IE6-9 */

}
</style>




          <div class="logo">
        <a href="/"><img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" /></a>     
      </div>    
        
                    



            <div id="impact-factor" class="official">
    <img src="/images/branding/official.gif" alt="official impact factor" title="2.12"/>
    <span id="impact-factor-value">2.12</span>
</div>
    
                            

<div class="module search gray small  " role="search">
    <div class="module-inner padded">
        <form method="get" class="searchForm"
              action=" /quickSearchRedirectURL "
              onsubmit="window.location.href=this['url'].value + '?terms=' + encodeURIComponent(this['terms'].value); return false;">
            <fieldset class="search">
			                <span>
                    Search <select name="url">
                                <option value="http://www.trialsjournal.com/search/results" selected>Trials</option>
                                <option value="http://www.biomedcentral.com/search/results">BioMed Central</option>
                           </select> for
                </span>
                            <input id="searchTerms" name="terms" type="text" alt="Search terms" class="text " />
                 <button class="w37" value="Go" type="submit">Go</button>
            </fieldset>
        </form>
    </div>
	<a class="advanced-search" href="/search">Advanced search</a>
</div> 

                        <div id="mobile-nav-list" >

	<ul class="primary-nav" role="navigation">
		<li     ><a href="/"><span id="home-tab">Home</span></a></li>
														<li             class="current"
    ><a href="/content"><span id="articles-tab">Articles</span></a></li>
										
	

	
            <li     ><a href="/authors/instructions"><span id="authors-tab">Authors</span></a></li>
        <li     ><a href="/about/reviewers"><span id="reviewers-tab">Reviewers</span></a></li>
    		<li     ><a href="/about"><span id='about-tab'>About this journal</span></a></li>
	<li     ><a href="/my"><span id="my-tab">My Trials</span></a></li>
		
    		</ul>
</div>
            </div>
</div>

<hr class="hide" />
<div class="container">
	<div id="content"  class="overflow-visible"  role="main">
			    
	

<!--div class="branding-mobile">
		<h1 class="logo">
	    <a href="/">
		    <img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" />
		</a>
		</h1>
	</div><br/-->



			
	



<div class="outline-wrapper block mobile-hidden" id="left-article-box">
<ul id="box-outline" class="box">
<ul id="outline" class="outline">
   <li>
      <a href="#">Top</a>
   </li>
   <li>
      <a href="#abs">Abstract</a>
   </li>
   <li>
      <a href="#sec1">Background</a>
   </li>
   <li>
      <a href="#sec2">Methods/design</a>
   </li>
   <li>
      <a href="#sec3">Discussion</a>
   </li>
   <li>
      <a href="#sec4">Endnotes</a>
   </li>
   <li>
      <a href="#sec5">Abbreviations</a>
   </li>
   <li>
      <a href="#sec6">Competing interests</a>
   </li>
   <li>
      <a href="#sec7">Authors’ contributions</a>
   </li>
   <li class="long">
      <a href="#sec8" class="clipped" onmouseover="outlineover(this)" onmouseout="outlineout(this)" title="Appendix 1: EPO-TBI unblinded project officer">Appendix 1: E...</a>
   </li>
   <li class="long">
      <a href="#sec9" class="clipped" onmouseover="outlineover(this)" onmouseout="outlineout(this)" title="Appendix 2: EPO-TBI outcome assessors">Appendix 2: E...</a>
   </li>
   <li class="long">
      <a href="#sec10" class="clipped" onmouseover="outlineover(this)" onmouseout="outlineout(this)" title="Appendix 3: EPO-TBI management committee">Appendix 3: E...</a>
   </li>
   <li class="long">
      <a href="#sec11" class="clipped" onmouseover="outlineover(this)" onmouseout="outlineout(this)" title="Appendix 4: EPO-TBI sites, principal investigator and research coordinator/s">Appendix 4: E...</a>
   </li>
   <li class="long">
      <a href="#sec12" class="clipped" onmouseover="outlineover(this)" onmouseout="outlineout(this)" title="Appendix 5: EPO-TBI French management team">Appendix 5: E...</a>
   </li>
   <li class="long">
      <a href="#sec13" class="clipped" onmouseover="outlineover(this)" onmouseout="outlineout(this)" title="Additional file">Additional fi...</a>
   </li>
   <li>
      <a href="#ack">Acknowledgements</a>
   </li>
   <li class="lowest">
      <a href="#refs">References</a>
   </li>
</ul>
</ul>

<dl id="box-outline1">
</dl>

				



</div>



<div class="mobile-hidden" id="right-panel">
 	
<div id="mobile-sidebar">
	<div id="mobile-sidebar-tab">
		<span>
			<a href="#" id="mobile-sidebar-tab-link"><img src="/images/sidebar-hidden.png"><img style="display:none;" src="/images/sidebar-shown.png"></a>
		</span>
	</div>	<div id="mobile-sidebar-list">

<div id="article-navigation-bar">
    <div class="issue-information block">
        <h5><a href="http://www.trialsjournal.com"><strong>Trials</strong></a></h5>
 		        <ul class="square normal">
            <li><a href="http://www.trialsjournal.com/content/16">Volume 16</a></li>
				
                    </ul>
    </div>

    <div class="article-information block" id="article-info">
        


<div id="viewing-options-links">
	<h5>Viewing options</h5>
	<ul class="square normal">
        
            <li>
                             <a onclick="_gaq.push(['_trackEvent', 'Abstract', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/16/1/39/abstract">Abstract</a>
                        </li>
        				<li>
							<strong>Full text</strong>
					</li>
				
		<li class="pdfFileSize">
			<a onclick="_gaq.push(['_trackEvent', 'PDF download', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/pdf/s13063-014-0528-6.pdf">PDF</a>
			<span>(580KB)</span>
		</li>

        
				<li>
						<a onclick="_gaq.push(['_trackEvent', 'additional files', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/16/1/39/additional">Additional files</a>
					</li>
			</ul>

        
</div>
		
<div id="associated-material-links">
    <h5>Associated material</h5>
    <ul class="square normal">
                                    <li><a onclick="_gaq.push(['_trackEvent', 'Article metrics', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/16/1/39/about">Article metrics</a></li>
                <li>
                        <a onclick="_gaq.push(['_trackEvent', 'Readers comments', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/16/1/39/comments">Readers' comments </a>
                    </li>
        <li>
                            <a onclick="_gaq.push(['_trackEvent', 'Pre-publication history', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/16/1/39/prepub">Pre-publication history</a>                    </li>
    </ul>
</div>
		




<div id="related-literature-links">
    <h5>Related literature</h5>
    <ul class="normal">
                    <li><a onclick="_gaq.push(['_trackEvent', 'Citied by', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://www.trialsjournal.com/content/16/1/39/about#citations">Cited by</a></li>
                <li id="google-blog-search"><a onclick="_gaq.push(['_trackEvent', 'Google blog search', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://www.google.com/search?tbm=blg&hl=en&amp;source=hp&amp;biw=1280&amp;bih=899&amp;q=%22Erythropoietin+in+traumatic+brain+injury%3A+study+protocol+for+a+randomised+controlled+trial%22&amp;btnG=Search">Google blog search</a></li>
        <h6>Other articles by authors</h6>
        <li>
            <a class="collapser"><i>&nbsp;</i>on Google Scholar</a>
<ul id="authg" class="hidebeforeload">                         <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22A+Nichol%22">Nichol A</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22C+French%22">French C</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22L+Little%22">Little L</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22J+Presneill%22">Presneill J</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22DJ+Cooper%22">Cooper DJ</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22S+Haddad%22">Haddad S</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22J+Duranteau%22">Duranteau J</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22O+Huet%22">Huet O</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22M+Skrifvars%22">Skrifvars M</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22Y+Arabi%22">Arabi Y</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22R+Bellomo%22">Bellomo R</a>
            </li>
                        </ul>          </li>
                <li>
            	        </li>
    </ul>     <h6>Related articles/pages</h6>
    <ul class="square normal">
        <li><a onclick="_gaq.push(['_trackEvent', 'on google', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://www.google.co.uk/search?hl=en&amp;q=related:http://www.trialsjournal.com/content/16/1/39">on Google</a></li>
        <li><a onclick="_gaq.push(['_trackEvent', 'on google scholar', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://scholar.google.com/scholar?q=related:http://www.trialsjournal.com/content/16/1/39">on Google Scholar</a></li>
            </ul>

</div>		
        
    
    
        

    	






<h5>Tools</h5>
	<ul class="square normal">
									<li>
						<a onclick="_gaq.push(['_trackEvent', 'download references', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/16/1/39/citation">Download references</a>
					</li>
				<li><a onclick="_gaq.push(['_trackEvent', 'download xml', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/download/xml/s13063-014-0528-6.xml">Download XML</a></li>
				<li>
						<a onclick="_gaq.push(['_trackEvent', 'email2friend', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/16/1/39/email">Email to a friend</a>
					</li>
		<li><a onclick="_gaq.push(['_trackEvent', 'order reprints', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186/s13063-014-0528-6&volume=16&issue=1&title=Erythropoietin+in+traumatic+brain+injury%3A+study+protocol+for+a+randomised+controlled+trial&author_name=Alistair Nichol&start_page=1&end_page=10">Order reprints</a></li>
		<li>
						<a onclick="_gaq.push(['_trackEvent', 'post a comment', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/16/1/39/postcomment">Post a comment</a>
					</li>			
		<ul id="download-to-links">
			<a class="downloadto_title btn" href="#"><span class="icon">&nbsp;</span>Download to ...</a>
			
			<ul id="downloadto" class="iconlist hidebeforeload" style="display: none;">
				<li>
					<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F39" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/39', 1, true]);"><span class="share-icons papers"></span>Papers</a>
				</li>
				<li>
					<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/39" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/39', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
				</li>
			</ul>
		</ul>
		
		<ul id="mobile-downloadto" class="iconlist">
		
		<h6>Download to ...</h6>
			<li>
				<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F39" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/39', 1, true]);"><span class="share-icons papers"></span>Papers</a>
			</li>
			
			<li>
				<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/39" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/39', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
		</ul>

		
	</ul>
		




<h5>Share this article</h5>
<ul id="social-networking-links">
	<li>
	<div class="fb-like" onclick="_gaq.push(['_trackEvent', 'Facebook Recommend', 'Article Sidebar', '/content/16/1/39', 1, true]);" data-href="http://www.trialsjournal.com/content/16/1/39" data-send="false" data-layout="button_count" data-width="100" data-show-faces="false" data-action="recommend"></div>
	</li>
	<li>
		<a onclick="_gaq.push(['_trackEvent', 'Share Twitter Recommend', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://twitter.com/share" data-url="http://www.trialsjournal.com/content/16/1/39" data-counturl="http://www.trialsjournal.com/content/16/1/39" data-hashtags="trials
" data-text="Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial" class="twitter-share-button">Tweet</a>
	</li>
	<li>
			<g:plusone size="medium" width="100"></g:plusone>
	</li>

        <li>
        <wb:share-button onclick="_gaq.push(['_trackEvent', 'Recommend Google plus', 'Article Sidebar', '/content/16/1/39', 1, true]);" addition="number" type="button" ralateUid="2216240737" title="Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial http://www.trialsjournal.com/content/16/1/39"></wb:share-button>
    </li>
    
		<a class="sharethis_title btn" href="#"><span class="icon">&nbsp;</span>More options...</a>
	<ul class="iconlist hidebeforeload" id="sharethis">
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'citeu Like', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://www.citeulike.org/posturl?url=http://www.trialsjournal.com/content/16/1/39"><span class="share-icons citeulike"></span>Citeulike</a>
			</li>
				<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Linkedin', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://www.linkedin.com/shareArticle?mini=true&url=%26%2335%3Btrials%0D%0AErythropoietin%20in%20traumatic%20brain%20injury%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F39&title=Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial"><span class="share-icons linkedin"></span>LinkedIn</a>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share delicious', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://del.icio.us/post?url=http://www.trialsjournal.com/content/16/1/39&title=Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial"><span class="share-icons delicious"></span>Del.icio.us</a>
	</li>
			<li>
				<a onclick="_gaq.push(['_trackEvent', 'Share via email', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="/content/16/1/39/email"><span class="share-icons email"></span>Email</a>
	</li>
			<li>
				<a onclick="target="_blank" onclick="_gaq.push(['_trackEvent', 'Share facebook', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://www.facebook.com/sharer.php?u=http://www.trialsjournal.com/content/16/1/39"><span class="share-icons facebook"></span>Facebook</a>
	</li>
	<li class="gp">
			<div class="googlehider mobile-hide"> 
				<div class="g-plusone" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus mobile-hide"></span>
				<div class="googlehider2 mobile-hide"> 
				<div class="g-plusone mobile-hide" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus"></span>
				<span class="gp-link"><a  onclick="_gaq.push(['_trackEvent', 'Share google plus', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="#">Google+</a></span>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Mandeley', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/39"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
			<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share twitter icon', 'Article Sidebar', '/content/16/1/39', 1, true]);" href="http://twitter.com/?status=Erythropoietin%20in%20traumatic%20brain%20injury%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F39+%23trials
"><span class="share-icons twitter"></span>Twitter</a>
			</li>

			<li><a href="http://www.reddit.com/submit" onclick="window.location = 'http://www.reddit.com/submit?url=http://www.trialsjournal.com/content/16/1/39'; return false"> <span class="share-icons reddit"></span>Reddit</a>
    </li>






		</ul>
</ul>

    </div>

    
  
        
                
        


















                                                                                
	

	    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="signup-to-etoc" class="button-collection-margins block mobile-border-bottom">	
					<h3>Email updates</h3>
			<p id="receive_issue_alerts_journal_updates_text">Keep up to date with the latest news and content from Trials and BioMed Central.</p>
			
				
<form  id="articleSignupForUpdates"  method="post" action="/signuptoupdates.html">
	<div id="message-box"></div>
    <fieldset class="block-form">
        <input type="text" name="emailAddress" onblur="javascript: if (this.value == '') { this.value = 'email address'; }" onfocus="javascript: if (this.value == 'email address') { this.value = ''; }" value="email address"  class="text " id="email" />
        <input value="" type="hidden" name="returnUrl" id="returnUrl" />
        <input value="xniche-trials" type="hidden" name="listName" id="listName" />
        <input value="Trials" type="hidden" name="journalName" id="journalName" />
        <button onclick="_gaq.push('_trackEvent', 'Signup', 'Signup for Email updates', "Trials");" class="w74 right" type="submit" onmouseover="this.className='w74 hover right'" onmouseout="this.className='w74 right'" value="Sign up">Sign up</button>
    </fieldset>
</form>	
</div>

	


			<div id="advert-offset">
    					
		<dl class="google-ad  ">
	<dt class="hide">
				
					<a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
			</dt>
		<dd>

		<!-- OAS AD 'Right3' begin -->
		<script type="text/javascript">
		OAS_AD('Right3');

		</script>
		<!-- OAS AD 'Right3' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad  noscript">  
    <dt class="hide"><a href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/014/0528/6/17537507573@Right3?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/014/0528/6/17395807853@Right3?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
					</div>
	

	
</div>
		<div class="mobile-sidebar-gradient top"></div>
		<div class="mobile-sidebar-gradient bottom"></div>
	</div>

</div>








 </div>
<div class="rounded custom white article full-text">
<div class="wrap-inner content">
    <div class="padded-inner">            


    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="topmatter">
	


	   






 
  



				<a href="/about/access"><img alt="Open Access" src="/images/articles/openaccess-large.png" class="access mr15"/></a>
					<span class="articletype">Study protocol</span>

<h1>Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial</h1>
        
			<div class="multipleins">
		
	<p class="authors">
        																																																																																																																																																																																																																																																																																																																																																																																															         <strong>Alistair Nichol</strong><sup><a href="/content/16/1/39/#ins1">1</a></sup><sup><a href="/content/16/1/39/#ins2">2</a></sup><sup><a href="/content/16/1/39/#ins3">3</a></sup><sup><a href="/content/16/1/39/#ins4">4</a></sup>, <strong>Craig French</strong><sup><a href="/content/16/1/39/#ins5">5</a></sup><sup><a href="/content/16/1/39/#ins6">6</a></sup>, <strong>Lorraine Little</strong><sup><a href="/content/16/1/39/#ins1">1</a></sup>, <strong>Jeffrey Presneill</strong><sup><a href="/content/16/1/39/#ins1">1</a></sup><sup><a href="/content/16/1/39/#ins7">7</a></sup>, <strong>D James Cooper</strong><sup><a href="/content/16/1/39/#ins1">1</a></sup><sup><a href="/content/16/1/39/#ins2">2</a></sup>, <strong>Samir Haddad</strong><sup><a href="/content/16/1/39/#ins1">1</a></sup><sup><a href="/content/16/1/39/#ins8">8</a></sup>, <strong>Jacques Duranteau</strong><sup><a href="/content/16/1/39/#ins1">1</a></sup><sup><a href="/content/16/1/39/#ins9">9</a></sup>, <strong>Olivier Huet</strong><sup><a href="/content/16/1/39/#ins10">10</a></sup>, <strong>Markus Skrifvars</strong><sup><a href="/content/16/1/39/#ins11">11</a></sup>, <strong>Yaseen Arabi</strong><sup><a href="/content/16/1/39/#ins1">1</a></sup><sup><a href="/content/16/1/39/#ins12">12</a></sup>, <strong>Rinaldo Bellomo</strong><sup><a href="/content/16/1/39/#ins1">1</a></sup><sup><a href="/content/16/1/39/#ins13">13</a></sup><sup><a href="/content/16/1/39/#ins6">6</a></sup><sup>&#42;</sup> and <strong>On behalf of the EPO-TBI Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group</strong>	</p>
	
				<div id="affiliations">
		<div class="module gray  inner">
<div class="module-inner padded-inner">
		<ul>
			<li>                                                                                                                                                
                                        		<p class="authors" >
							<span>*</span>
									 Corresponding author:										            Rinaldo  Bellomo <a href='mailto:rinaldo.bellomo@austin.org.au'>rinaldo.bellomo@austin.org.au</a>    					</p>
      
</li>
			
                                                                                                                                                                                                                                                                                                                                                                		</ul>

		
		 <p class="options"><a class="affiliations-toggle" href="#"><i class="arrow"></i>Author Affiliations</a></p>            <section> 
						<div class="collapsible-content">
							
				<div id="ins_container" style="display: block;">
										    						    <p >
						        <sup id="ins1">1</sup>                                Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne 3004, Australia
                            </p>
																    						    <p >
						        <sup id="ins2">2</sup>                                Department of Intensive Care Medicine, The Alfred, Commercial Road, Melbourne 3004, Australia
                            </p>
																    						    <p >
						        <sup id="ins3">3</sup>                                Department of Anaesthesia and Intensive Care Medicine, St Vincent’s University Hospital, Elm Park, Dublin 4, Ireland
                            </p>
																    						    <p >
						        <sup id="ins4">4</sup>                                School of Medicine and Medical Sciences, University College Dublin, Elm Park, Dublin 4, Ireland
                            </p>
																    						    <p >
						        <sup id="ins5">5</sup>                                Department of Intensive Care, Western Health, Gordon Street, Footscray 3011, Australia
                            </p>
																    						    <p >
						        <sup id="ins6">6</sup>                                Department of Medicine North West Academic Centre, The University of Melbourne, Grattan Street, Parkville 3052, Australia
                            </p>
																    						    <p >
						        <sup id="ins7">7</sup>                                Department of Intensive Care, Mater Health Services, Raymond Terrace, South Brisbane 4101, Australia
                            </p>
																    						    <p >
						        <sup id="ins8">8</sup>                                Department of Intensive Care, King Abdulaziz Medical City, Riyadh 11426, Kingdom of Saudi Arabia
                            </p>
																    						    <p >
						        <sup id="ins9">9</sup>                                Service d’Anesthésie-Réanimation, Hôpitaux universitaires Paris Sud, Assistance Publique des Hôpitaux de Paris, Hôpital de Bicêtre, 78, rue du Général Leclerc, Le Kremlin Bicêtre, 94275, France
                            </p>
																    						    <p >
						        <sup id="ins10">10</sup>                                Department of Anesthesiology and Intensive Care Medicine, Centre Hospitalier Universitaire La Cavale Blanche Université de Bretagne Ouest, Brest Cedex, 29609, France
                            </p>
																    						    <p >
						        <sup id="ins11">11</sup>                                Department of Anaesthesiology and Intensive Care Medicine, Helsinki University Hospital, Helsinki, FIN-00029, Finland
                            </p>
																    						    <p >
						        <sup id="ins12">12</sup>                                Intensive Care Department, College of Medicine King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh 11426, Kingdom of Saudi Arabia
                            </p>
																    						    <p >
						        <sup id="ins13">13</sup>                                Department of Intensive Care, Austin Health, Studley Road, Heidelberg 3084, Australia
                            </p>
																
				</div>
										<p id="authoremails">            For all author emails, please <a href="/logon">log on</a>.
    </p>
						</div>
			</section>
				</div>
</div>
		</div>
	  </div>

            <section class="cit">
                        <div class="collapsible-content">
        <p><em>Trials</em> 2015, <strong>16</strong>:39&nbsp;
			<span class="pseudotab">doi:10.1186/s13063-014-0528-6</span></p>
	    				    
    
        
                
		<p>The electronic version of this article is the complete one and can be found online at: <a href="http://www.trialsjournal.com/content/16/1/39">http://www.trialsjournal.com/content/16/1/39</a></p>
		<br/>
                    <table cellspacing="0" cellpadding="0">
        <tbody>
        <tr><td>Received:</td><td>5 September 2014</td></tr>                <tr><td>Accepted:</td><td>19 December 2014</td></tr>        <tr><td>Published:</td><td>8 February 2015</td></tr>        </tbody>
        </table>
    		<!--<br/>-->
		<div  style="line-height:140%">
        <p>
            &copy; 2015 Nichol et al.; licensee BioMed Central. <br />
        </p>
					<p>
				This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
			</p>
		    	</div>
	</section>

</div>
<div id="article-body">
    <section><a name="abs"></a><h3>Abstract</h3>
   <div class="collapsible-content">
      <h4>Background</h4>
      <p style="line-height:160%">Traumatic brain injury is a leading cause of death and disability worldwide. Laboratory
         and clinical studies demonstrate a possible beneficial effect of erythropoietin in
         improving outcomes in the traumatic brain injury cohort. However, there are concerns
         regarding the association of erythropoietin and thrombosis in the critically ill.
         A large-scale, multi-centre, blinded, parallel-group, placebo-controlled, randomised
         trial is currently underway to address this hypothesis.
      </p>
      <h4>Methods/design</h4>
      <p style="line-height:160%">The erythropoietin in traumatic brain injury trial is a stratified prospective, multi-centre,
         randomised, blinded, parallel-group, placebo-controlled phase III trial. It aims to
         determine whether the administration of erythropoietin compared to placebo improves
         neurological outcome in patients with moderate or severe traumatic brain injury at
         six months after injury. The trial is designed to recruit 606 patients between 15
         and 65 years of age with severe (Glasgow Coma Score: 3 to 8) or moderate (Glasgow
         Coma Score: 9 to 12) traumatic brain injury in Australia, New Zealand, Kingdom of
         Saudi Arabia, France, Finland, Germany and Ireland.
      </p>
      <p style="line-height:160%">Trial patients will receive either subcutaneous erythropoietin or placebo within 24
         hours of injury, and weekly thereafter for up to three doses during the intensive
         care unit admission. The primary outcome will be the combined proportion of unfavourable
         neurological outcomes at six months: severe disability or death. Secondary outcomes
         will include the rate of proximal deep venous thrombosis detected by compression Doppler
         ultrasound, six-month mortality, the proportion of patients with composite vascular
         events (deep venous thrombosis, pulmonary embolism, myocardial infarction, cardiac
         arrest and cerebrovascular events) at six months and quality of life with health economic
         evaluations.
      </p>
      <h4>Discussion</h4>
      <p style="line-height:160%">When completed, the trial aims to provide evidence on the efficacy and safety of erythropoietin
         in traumatic brain injury patients, and to provide clear guidance for clinicians in
         their management of this devastating condition.
      </p>
      <h4>Trial registration</h4>
      <p style="line-height:160%">Australian New Zealand Clinical Trials registry: <a href="ACTRN12609000827235">ACTRN12609000827235</a> <a href="http://www.webcitation.org/query.php?url=ACTRN12609000827235&amp;refdoi=10.1186/s13063-014-0528-6" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a> (registered on 22 September 2009).
      </p>
      <p style="line-height:160%">Clinicaltrials.gov: <a href="NCT00987454">NCT00987454</a> <a href="http://www.webcitation.org/query.php?url=NCT00987454&amp;refdoi=10.1186/s13063-014-0528-6" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a> (registered on 29 September 2009). European Drug Regulatory Authorities Clinical
         Trials: 2011-005235-22 (registered on 18 January 2012).
      </p>
   </div>
</section><span id="keywords">
   <h5 class="inline">Keywords: </h5>Traumatic brain injury; Erythropoietin; Outcome; Critical care; Randomised controlled trials</span><section><a name="sec1"></a><h3>Background</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Traumatic brain injury (TBI) is a devastating condition which affects close to 1,000
         people each year in Australia, causes extensive long-term disability and suffering,
         which subsequently results in approximately 1 billion Australian dollars in lifetimes
         costs per year <a name="d75303e274"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>]. Disability follows from primary and secondary brain injury. Attenuation of secondary
         brain injury (decreasing the additional injury due to the inflammatory, excitotoxic
         and apoptotic response to trauma) is possible <a name="d75303e278"></a>[<a onclick="LoadInParent('#B2'); return false;" href="#B2">2</a>]. Erythropoietin (EPO) is a glycoprotein hormone with pleiotropic cytokine-like effects
         <a name="d75303e282"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>]. EPO has effects, independent of those on erythropoiesis, which are relevant to patients
         who have had a TBI. They include anti-apoptotic activity and protective neurological
         effects in the presence of hypoxia and ischaemia <a name="d75303e286"></a>[<a onclick="LoadInParent('#B2'); return false;" href="#B2">2</a>]-<a name="d75303e290"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>]. A neuroprotective effect of EPO has been demonstrated in animal models of TBI <a name="d75303e295"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>],<a name="d75303e299"></a>[<a onclick="LoadInParent('#B6'); return false;" href="#B6">6</a>]. A large, multi-centre, randomised controlled trial (RCT) demonstrated that EPO improved
         survival in a retrospectively identified trauma cohort <a name="d75303e303"></a>[<a onclick="LoadInParent('#B7'); return false;" href="#B7">7</a>]. A subsequent large RCT by the same group found that while EPO did not reduce transfusion
         rates, in a prospectively identified trauma cohort (including TBI) EPO significantly
         decreased 29-day mortality compared to a placebo (3.5 versus 6.6%) <a name="d75303e307"></a>[<a onclick="LoadInParent('#B8'); return false;" href="#B8">8</a>]. Additional observational studies and one very small RCT support the hypothesis that
         EPO may improve neurological outcomes after TBI <a name="d75303e311"></a>[<a onclick="LoadInParent('#B9'); return false;" href="#B9">9</a>],<a name="d75303e315"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>]. However, many concerns have been raised about the ability of EPO to increase the
         risk of venous thromboembolism (VTE) <a name="d75303e320"></a>[<a onclick="LoadInParent('#B8'); return false;" href="#B8">8</a>],<a name="d75303e324"></a>[<a onclick="LoadInParent('#B11'); return false;" href="#B11">11</a>],<a name="d75303e328"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>]. The United States Food and Drug Administration recently added a black box warning
         regarding this risk on EPO preparations. However, it is worth noting that the largest
         trial in the critically ill to date demonstrates a clear survival advantage in traumatically
         injured patients who are generally most vulnerable to VTE complications.
      </p>
      <p style="line-height:160%">The question of whether the administration of EPO benefits patients with TBI remains
         unanswered. To address this evidence gap we are undertaking a large multi-centre,
         blinded, parallel-group, placebo-controlled randomised trial comparing the administration
         of EPO with a placebo. This trial will be sufficiently powered to detect clinically
         relevant differences in neurological outcomes measured by the eight-level Extended
         Glasgow Outcome Scale (GOSE) <a name="d75303e334"></a>[<a onclick="LoadInParent('#B13'); return false;" href="#B13">13</a>] at six months following injury.
      </p>
   </div>
</section>
<section><a name="sec2"></a><h3>Methods/design</h3>
   <div class="collapsible-content">
      <h4>Trial design and outcomes</h4>
      <p style="line-height:160%">The erythropoietin in traumatic brain injury (EPO-TBI) trial is a stratified prospective,
         multi-centre, randomised, blinded, parallel-group, placebo-controlled phase III trial.
         It aims to determine whether the administration of EPO compared to a placebo improves
         neurological outcome in patients with moderate or severe TBI at six months after injury.
         The trial is designed to recruit 606 patients between 15 and 65 years of age with
         severe (Glasgow Coma Score(GCS): 3 to 8) or moderate (GCS: 9 to 12) TBI in Australia,
         New Zealand, Kingdom of Saudi Arabia, France, Finland, Germany and Ireland.
      </p>
      <h4>Participants</h4>
      <p style="line-height:160%">Patients aged between 15 and 65 years with non-penetrating moderate or severe TBI
         will be eligible for this trial. These criteria were designed to exclude patients
         with unsurvivable neurological injury, patients at a high risk of VTE and those who
         would be exposed to additional risk due to the trial drug.
      </p>
      <h4>Inclusion criteria</h4>
      <p style="line-height:160%">Patients with non-penetrating moderate (Glasgow Coma Score (GCS) 9–12) or severe (GCS
         3–8) traumatic brain injury admitted to an ICU who:
      </p>
      <p style="line-height:160%">1. Are ≥15 to ≤65 years of age<sup>a</sup></p>
      <p style="line-height:160%">2. Are &lt;24 hours since primary traumatic injury</p>
      <p style="line-height:160%">3. Are expected to stay ≥48 hours</p>
      <p style="line-height:160%">4. Have a haemoglobin not exceeding the upper limit of the applicable normal reference
         range in clinical use at the treating institution<sup>b</sup></p>
      <p style="line-height:160%">5. Have written informed consent from legal surrogate</p>
      <h4>Exclusion criteria</h4>
      <p style="line-height:160%">Patients are excluded from the study if any of the following criteria apply<sup>c</sup>:
      </p>
      <p style="line-height:160%">1. GCS = 3 and fixed dilated pupils</p>
      <p style="line-height:160%">2. History of deep vein thrombosis, pulmonary embolism or other thromboembolic event</p>
      <p style="line-height:160%">3. A chronic hypercoagulable disorder, including known malignancy</p>
      <p style="line-height:160%">4. Treatment with erythropoietin in the last 30 days</p>
      <p style="line-height:160%">5. First dose of study drug unable to be given within 24 hours of primary injury</p>
      <p style="line-height:160%">6. Pregnancy or lactation or 3 months post-partum</p>
      <p style="line-height:160%">7. Uncontrolled hypertension (systolic blood pressure &gt;200 mmHg or diastolic blood
         pressure &gt;110 mmHg)
      </p>
      <p style="line-height:160%">8. Acute myocardial infarct within the past 12 months</p>
      <p style="line-height:160%">9. Past history of epilepsy with seizures in past 3 months</p>
      <p style="line-height:160%">10. Expected to die imminently (&lt;24 hours)</p>
      <p style="line-height:160%">11. Inability to perform lower limb ultrasounds</p>
      <p style="line-height:160%">12. Known sensitivity to mammalian cell-derived products</p>
      <p style="line-height:160%">13. Hypersensitivity to the active substance or to any of the additives</p>
      <p style="line-height:160%">14. Pure red cell aplasia</p>
      <p style="line-height:160%">15. End-stage renal failure (receives chronic dialysis)</p>
      <p style="line-height:160%">16. Severe pre-existing physical or mental disability or severe co-morbidity that
         may interfere with the assessment of outcome
      </p>
      <p style="line-height:160%">17. Spinal cord injury</p>
      <p style="line-height:160%">18. Treatment with any investigational drug within 30 days before enrolment</p>
      <p style="line-height:160%">19. The treating physician believes it is not in the best interests of the patient
         to be randomised to this trial
      </p>
      <h4>Outcomes measures</h4>
      <p style="line-height:160%">The primary outcome of this trial is the patients’ neurological status at six months,
         summarized as a binary midpoint reduction of their eight-level Extended Glasgow Outcome
         Scale (GOSE) score, defined as favourable (GOSE score: 5 to 8; moderate disability
         and good recovery) or unfavourable (GOSE score: 1 to 4; death and severe disability).
      </p>
      <p style="line-height:160%">Secondary outcomes include:</p>
      <p style="line-height:160%">1. Neurological status at six months summarized by the eight-level GOSE</p>
      <p style="line-height:160%">2. Quality of life assessment using the Short Form 12 (SF-12) <a name="d75303e434"></a>[<a onclick="LoadInParent('#B14'); return false;" href="#B14">14</a>] and EuroQoL-5D (EQ-5D) <a name="d75303e438"></a>[<a onclick="LoadInParent('#B15'); return false;" href="#B15">15</a>] at six months
      </p>
      <p style="line-height:160%">3. Mortality at six months</p>
      <p style="line-height:160%">4. Proximal deep venous thrombosis (DVT) detected by ultrasound</p>
      <p style="line-height:160%">5. Occurrence of a thrombotic vascular event (including DVT, pulmonary embolism, myocardial
         infarction, cardiac arrest and cerebrovascular events) at six months. The definitions
         for these events are previously reported <a name="d75303e448"></a>[<a onclick="LoadInParent('#B16'); return false;" href="#B16">16</a>]
      </p>
      <p style="line-height:160%">6. Resource use and costs at six months</p>
      <p style="line-height:160%">7. Incremental cost effectiveness</p>
      <h4>Trial interventions</h4>
      <p style="line-height:160%">The intervention to be examined in this trial is the subcutaneous administration of
         erythropoietin 40,000 International Units (IU) compared to a placebo (0.9% saline).
      </p>
      <p style="line-height:160%">A summary of the trial interventions and follow up schedule is provided in Figure&nbsp;<a name="d75303e462"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/39/figure/F1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/39/figure/F1">1</a>.
         
      </p><div class="figs">
      <div class="fig"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/39/figure/F1','F1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/39/figure/F1"><img align="top" src="/content/figures/s13063-014-0528-6-1.gif" alt="thumbnail" class="thumbnail"><strong>Figure 1.</strong></a> <strong>Summary of trial treatment and follow up schedule.</strong> The baseline ultrasound may be performed before or at least within 48 hours after
         the first dose administration. EPO, Erythropoietin (Epoetin alfa) 40,000 IU or normal
         saline placebo; US, Ultrasound.
      </div></div>
      <h4>Investigational product</h4>
      <p style="line-height:160%">The trial drug is Epoetin alfa 40,000 IU in a pre-filled syringe, manufactured by
         Janssen-Cilag Pty Ltd, or the placebo sodium chloride 0.9. The trial drug will be
         administered by subcutaneous injection.
      </p>
      <p style="line-height:160%">For patients randomised to the treatment arm, an unblinded nurse will administer the
         full contents of the Epoetin alfa 40,000 IU pre-filled syringe to the patient. For
         patients randomised to the placebo arm, an unblinded nurse will administer 1 mL from
         a sodium chloride 0.9% 10 mL ampoule.
      </p>
      <p style="line-height:160%">The first dose will be given within 24 hours of the estimated time of TBI, and then
         weekly for up to two more doses (on trial days eight and 15). The trial drug will
         only be administered to patients during the ICU admission. If the patient is discharged
         to the general ward (before trial day eight or before day 15) they will not receive
         any further doses of trial drug. Patients readmitted to ICU during the same hospital
         stay will not receive any further doses of the trial drug.
      </p>
      <h4>Variable haemoglobin threshold for dosing to reduce the risk of thromboembolic complications</h4>
      <p style="line-height:160%">Previous trials examining the long-term use of EPO in renal failure <a name="d75303e495"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>] and cancer <a name="d75303e499"></a>[<a onclick="LoadInParent('#B11'); return false;" href="#B11">11</a>] patients targeting haemoglobin (Hb) concentrations above 120 g/L (12 g/dL) have demonstrated
         an increased risk of thromboembolic complications. Observational studies also demonstrate
         that the Hb concentration in critically ill patients falls rapidly in the first 72
         hours of admission <a name="d75303e503"></a>[<a onclick="LoadInParent('#B17'); return false;" href="#B17">17</a>],<a name="d75303e507"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>]. A dosing structure based on Hb concentration was developed to address the known
         risks of thromboembolic complications associated with EPO use: the first dose of trial
         drug is administered only if the haemoglobin (Hb) concentration is less than the upper
         limit of the applicable normal reference range in clinical use at the treating institution;
         the second and third doses are administered only if the Hb concentration is &lt;120 g/L
         (12 g/dL).
      </p>
      <p style="line-height:160%">The second (trial day eight) and third (trial day 15) doses may be given the day before
         or after dosing day, so the trial drug is prepared in pharmacy business hours. The
         weekly dose will not be administered if the patient’s pre-medication Hb is ≥120 g/L
         (12 g/dL); the trial drug will be temporarily withheld for that dose. The patient
         will be assessed on the next scheduled dosing day. If their Hb is &lt;120 g/L (12 g/dL),
         the dose may be given if the patient is still in the ICU and has not met the permanent
         withholding criteria.
      </p>
      <p style="line-height:160%">At Johannes Gutenberg-Universtität, Mainz Germany an additional temporary trial drug
         withholding criterion applies. The weekly dose will not be administered if the patient
         has a refractory high blood pressure; the trial drug will be withheld for that dose,
         and the patient will be assessed on the next scheduled dosing day. No further doses
         will be administered if the patient has met any permanent withholding criteria.
      </p>
      <p style="line-height:160%">Permanent withholding criteria:</p>
      <p style="line-height:160%">1. Development of proximal deep venous thrombosis</p>
      <p style="line-height:160%">2. Development of pulmonary embolism</p>
      <p style="line-height:160%">3. Any other thrombotic event</p>
      <p style="line-height:160%">4. Acute myocardial infarction</p>
      <p style="line-height:160%">5. Cardiac arrest or ventricular fibrillation</p>
      <p style="line-height:160%">6. Cerebrovascular accident</p>
      <p style="line-height:160%">7. Any serious adverse event or protocol deviation where, in the attending physician’s
         opinion, the patient should not receive any further doses of the trial drug
      </p>
      <p style="line-height:160%">8. Consent has been withdrawn or consent to continue has not been granted</p>
      <h4>Management of traumatic brain injury</h4>
      <p style="line-height:160%">The ICU medical team will have full independent control of patient management, however
         the trial management committee request that standardised TBI clinical practice follows
         Brain Trauma Foundation <a name="d75303e540"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>] guidelines.
      </p>
      <h4>Compression Doppler ultrasound</h4>
      <p style="line-height:160%">Critically ill patients are at risk of VTE complications. Previous studies, which
         did not specifically screen for VTE, have demonstrated an association of EPO with
         increased rates of VTE. The true risk is unknown in the critically ill as clinical
         examination has severe limitations, and many clinically undetected VTE complications
         are revealed when prospective screening is performed. The risk of VTE in the traumatically
         injured patients is potentially further elevated, as concerns regarding intracerebral
         haemorrhage frequently discourage clinicians giving pharmaceutical agents (low molecular
         weight heparins) to mitigate this risk. Therefore, to address this potential and largely
         unknown risk of EPO in the traumatically injured patients, we designed a prospective
         VTE screening algorithm. Bilateral compression Doppler ultrasound of the lower extremities
         will be performed to monitor for proximal DVT at baseline (before the first dose if
         possible, or at least within 48 hours after the first dose administration) then twice
         weekly after each dose of the trial drug for three weeks or up to ICU discharge, whichever
         occurs first. The procedure for the ultrasound was standardised, with evaluation of
         the following veins: common femoral, proximal femoral, mid femoral, distal femoral,
         popliteal and trifurcation.
      </p>
      <p style="line-height:160%">Up to six scheduled twice weekly ultrasounds will be performed if the patient is an
         inpatient in the ICU for longer than three weeks. No further scheduled twice weekly
         ultrasounds are required beyond trial day 21.
      </p>
      <p style="line-height:160%">If the patient meets a temporary or permanent withholding criteria and remains in
         the ICU, the twice weekly compression Doppler ultrasounds are performed up to trial
         day 21 or ICU discharge, whichever occurs first.
      </p>
      <p style="line-height:160%">Bilateral compression Doppler ultrasounds will be performed on the general ward if
         the patient has been transferred after a dose of the trial drug and before a scheduled
         ultrasound has been performed. This will ensure at least one bilateral compression
         Doppler ultrasound will be performed after each dose of the trial drug.
      </p>
      <p style="line-height:160%">The site treating clinicians outside the ICU (known variously by names such as Parent
         Unit, Admitting Unit or Attending Medical Service) are required to notify the site
         researchers of any occurrences of VTE as soon as it is diagnosed.
      </p>
      <p style="line-height:160%">Additional bilateral compression Doppler ultrasounds will be performed on suspicion
         of DVT or pulmonary embolism. The treating clinician may therefore take additional
         measures to reduce the risk of complications from any identified thrombosis. We anticipate
         that this algorithm will mitigate any additional risk that could be posed by the use
         of EPO in this cohort.
      </p>
      <h4>Randomisation and allocation concealment</h4>
      <p style="line-height:160%">Concealed randomisation will be performed via a web-based system that includes block
         randomisation at each site. Treatment allocation will be stratified by site and also
         by the severity of TBI at randomisation (moderate (GCS: 9 to 12) or severe (GCS: 3
         to 8).
      </p>
      <p style="line-height:160%">Bias will be minimised by concealed random allocation by the use of a robust primary
         outcome minimally susceptible to ascertainment bias, and by blinded assessment of
         the primary outcome by a trained outcome assessor at the coordinating centre (Australia
         and New Zealand) or by trained, blinded outcome assessors in each country in Europe
         and the Kingdom of Saudi Arabia.
      </p>
      <h4>Blinding plan</h4>
      <p style="line-height:160%">Site personnel will be blinded to treatment allocation. For the efficient conduct
         of the trial the site pharmacists, site unblinded dosing nurses and the pharmacists
         at the central pharmacy in France (Clinical Trial Department of the Pharmaceutical
         Establishment of Assistance Publique-Hôpitaux de Paris) will be unblinded to treatment
         assignment.
      </p>
      <p style="line-height:160%">Staff at the coordinating centre will be blinded to treatment allocation, except for
         an unblinded project officer (Appendix 1) and designee, the analyst programmers responsible
         for the web-based data management system and a nominated statistician who will supervise
         data extraction from the database for interim and final analyses. The French management
         team will be blinded to treatment assignment.
      </p>
      <p style="line-height:160%">Following patient randomisation by the site investigator or designee, an unblinded
         trial pharmacist will dispense the trial drug in a tamperproof sealed opaque box (Figure&nbsp;<a name="d75303e578"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/39/figure/F2','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/39/figure/F2">2</a>) to blind the treatment assignment. The box may only be opened by the site’s designated
         unblinded trial dosing nurse. For patients who receive the active treatment the sealed
         box will consist of one Epoetin alfa 40,000 IU pre-filled syringe labelled with direction
         for use ‘Inject 1 ml subcutaneously over at least 1 minute’. For patients who receive
         the placebo the sealed box will consist of one sodium chloride 0.9% 10 mL ampoule
         labelled with direction for use ‘Inject 1 ml subcutaneously over at least 1 minute’.
         
      </p><div class="figs">
      <div class="fig"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/39/figure/F2','F2',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/39/figure/F2"><img align="top" src="/content/figures/s13063-014-0528-6-2.gif" alt="thumbnail" class="thumbnail"><strong>Figure 2.</strong></a> <strong>Blinded tamperproof sealed box.</strong></div></div>
      <p style="line-height:160%">For safety reasons, unblinded dosing nurses will be allocated in each research site
         to administer EPO or placebo doses discreetly, with a screen around the patient bed
         area. The trial drug or placebo dose may be checked with a second unblinded nurse
         if required to comply with local hospital regulations. After dose administration the
         unblinded dosing nurse will discard the used trial drug in such a manner as to maintain
         the blind. These unblinded dosing nurses will have access to the unblinded trial pharmacist.
         Unblinded dosing nurses will not be involved in the care of a trial patient and may
         not discuss trial drug treatment with research staff or other members of the ICU or
         hospital staff.
      </p>
      <h4>Data collection and management</h4>
      <p style="line-height:160%">All data will be collected by trained staff at each trial site using a paper source
         document developed by the coordinating centre. Data will then be entered into a web
         database designed by the trial project manager in collaboration with the Monash University
         Monash University Clinical Informatics and Data Management Unit. Data queries will
         be automatically generated via the electronic data collection database, and at monitoring
         by the trial project manager or the clinical research associate (in France).
      </p>
      <p style="line-height:160%">Randomised patients will be followed up to death or six months post-randomisation
         (whichever occurs first). Data collection will be restricted primarily to those variables
         necessary to define clinical patient characteristics including: baseline demographics,
         primary diagnoses, physiological parameters, Acute Physiology and Chronic Health Evaluation
         II (APACHE II), Injury Severity Score (ISS), Abbreviated Injury Severity Score (AIS)
         and Computed Tomography Brain Marshall Score <a name="d75303e604"></a>[<a onclick="LoadInParent('#B20'); return false;" href="#B20">20</a>], diagnostic interventions, therapeutic interventions, and documentation of deaths
         and other serious adverse events (SAE).
      </p>
      <p style="line-height:160%">To prepare for the six-month follow-up assessment, patients and/or their legal surrogate
         will be asked to provide three possible points of contact (home and close family contact
         details) to the research staff prior to hospital discharge. Full protocol data will
         be collected in all patients including those excluded at any stage. Patients who are
         alive at six months after randomisation (or their carer or proxy if more appropriate)
         will be interviewed by a trained outcome assessor from Monash University for patients
         in Australia and New Zealand, or trained outcome assessors in each country in Europe
         and the Kingdom of Saudi Arabia. The regional assessors will use a standardized structured
         telephone questionnaire <a name="d75303e610"></a>[<a onclick="LoadInParent('#B21'); return false;" href="#B21">21</a>] to measure the eight-level GOSE <a name="d75303e614"></a>[<a onclick="LoadInParent('#B13'); return false;" href="#B13">13</a>]. Neurological outcomes will then be defined as favourable (GOSE score: 5 to 8; moderate
         disability and good recovery) or unfavourable (GOSE score: 1 to 4; death and severe
         disability). Patients subsequently withdrawn for any reason (DVT, pulmonary embolism,
         myocardial infarction, cerebrovascular accident, cardiac arrest, or an SAE) or who
         did not receive the trial drug will be followed up on, according to the study follow-up
         schedule, and analysed according to the modified intention-to-treat principle <a name="d75303e618"></a>[<a onclick="LoadInParent('#B22'); return false;" href="#B22">22</a>],<a name="d75303e622"></a>[<a onclick="LoadInParent('#B23'); return false;" href="#B23">23</a>].
      </p>
      <p style="line-height:160%">Trained outcome assessors (Appendix 2) will collect data for surviving patients at
         six months for quality of life assessment using the EQ-5D <a name="d75303e628"></a>[<a onclick="LoadInParent('#B15'); return false;" href="#B15">15</a>] questionnaire and the SF-12 <a name="d75303e632"></a>[<a onclick="LoadInParent('#B14'); return false;" href="#B14">14</a>] questionnaire. If the patient is not well enough or not available to complete the
         questionnaires, the SF-12 questionnaire will not be completed <a name="d75303e636"></a>[<a onclick="LoadInParent('#B24'); return false;" href="#B24">24</a>],<a name="d75303e640"></a>[<a onclick="LoadInParent('#B25'); return false;" href="#B25">25</a>] and quality of life will not be assessed for that patient.
      </p>
      <p style="line-height:160%">Data will be collected from surviving patients at six months for cost effectiveness
         analysis, with utilities calculated using the EQ-5D <a name="d75303e646"></a>[<a onclick="LoadInParent('#B15'); return false;" href="#B15">15</a>] results, and costs will be calculated based on ICU, acute and post-acute care resource
         use. If the patient is not well enough or not available to complete the EQ-5D the
         patient’s proxy will be asked to complete it for the patient.
      </p>
      <p style="line-height:160%">The outcome assessments will be monitored by an experienced and trained outcome assessor
         at Monash University.
      </p>
      <h4>Ethical issues</h4>
      <p style="line-height:160%">This is a trial conducted in patients who are unconscious and unable to consent to
         participation, therefore the patient’s legal surrogate will be approached to provide
         consent for the patient. Patients who recover sufficient cognition to understand the
         explanation of the trial will additionally be asked to consent to continue in the
         trial if this is required under the ethics committee approval conditions.
      </p>
      <p style="line-height:160%">In France patients may be enrolled under an Emergency clause. Informed consent was
         obtained from each patient’s legal surrogate for participation in the trial.
      </p>
      <p style="line-height:160%">Approval for this protocol has been obtained from appropriate regulatory authorities,
         and from participating hospitals’ human research ethics committees. The list of responsible
         ethics committees is provided as an Additional file <a name="d75303e661"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/39/suppl/S1','',630,470); return false;" href="http://www.trialsjournal.com/content/16/1/39/suppl/S1">1</a>.
      </p>
      <h4>Sample size and power</h4>
      <p style="line-height:160%">The estimated rate of unfavourable neurological outcome (death and severe disability)
         in Australian and New Zealand patients with moderate and severe TBI <a name="d75303e671"></a>[<a onclick="LoadInParent('#B26'); return false;" href="#B26">26</a>],<a name="d75303e675"></a>[<a onclick="LoadInParent('#B27'); return false;" href="#B27">27</a>] is approximately 50%.
      </p>
      <p style="line-height:160%">A trial of 574 patients will have a 90% power at an alpha of 0.05 to detect a 14%
         absolute risk reduction (50 versus 36%) and 80% power to detect a 12% (50 versus 38%)
         absolute risk reduction in unfavourable neurological outcome. A trial of this size
         was also estimated to have 80% power to detect a 9% absolute risk increase in proximal
         lower limb DVT from an assumed baseline proportion of 18% (50% increase in relative
         risk) at a one-sided alpha of 0.05. Allowing for a 5% withdrawal and loss to follow-up
         rate, we will recruit 606 patients to prevent any loss of power and to conduct an
         adequately powered modified intention-to-treat analysis <a name="d75303e681"></a>[<a onclick="LoadInParent('#B22'); return false;" href="#B22">22</a>],<a name="d75303e685"></a>[<a onclick="LoadInParent('#B23'); return false;" href="#B23">23</a>].
      </p>
      <h4>Statistical analysis</h4>
      <p style="line-height:160%">Independent senior statisticians at Monash University Department of Epidemiology and
         Preventive Medicine will perform data analyses following a detailed statistical analysis
         plan, which will be published separately in the journal <em>Trials</em>.
      </p>
      <p style="line-height:160%">A modified intention-to-treat analysis will be performed based on all randomly assigned
         patients, except those withdrawing consent for use of all trial data, those not fulfilling
         inclusion criteria and those who never receive the intervention <a name="d75303e700"></a>[<a onclick="LoadInParent('#B22'); return false;" href="#B22">22</a>],<a name="d75303e704"></a>[<a onclick="LoadInParent('#B23'); return false;" href="#B23">23</a>]. Baseline variables will be summarised using descriptive statistics. The trial primary
         outcome will be compared between treatments with an unadjusted risk ratio and 95%
         confidence interval. Sensitivity analyses will be performed using logistic regression
         adjusting for stratification factors, pre-specified prognostic factors and any other
         baseline covariates exhibiting substantial imbalance between randomisation arms. Furthermore,
         a proportional odds cumulative logit model <a name="d75303e708"></a>[<a onclick="LoadInParent('#B28'); return false;" href="#B28">28</a>],<a name="d75303e712"></a>[<a onclick="LoadInParent('#B29'); return false;" href="#B29">29</a>], adjusting for relevant covariates, will be applied to the eight-level vector of
         the six-month GOSE score.
      </p>
      <p style="line-height:160%">Other secondary analyses, including assessment of outcomes according to actual treatment
         received, quality of life assessment, mortality at hospital discharge and six months
         and incidence of adverse events (AE), will be compared between treatment groups using
         unadjusted and adjusted logistic regression and log-binomial regression. Pre-specified
         subgroup analyses will be obtained using interaction terms in logistic regression
         models. Adjusted effect estimates of the EPO intervention, derived from logistic and
         proportional odds ordinal logistic models, will be reported as adjusted risk ratios
         averaged over the remaining covariates, as recently recommended <a name="d75303e718"></a>[<a onclick="LoadInParent('#B30'); return false;" href="#B30">30</a>]-<a name="d75303e722"></a>[<a onclick="LoadInParent('#B32'); return false;" href="#B32">32</a>]. Time-to-event analyses will be undertaken using Kaplan-Meier curves, as well as
         unadjusted and adjusted Cox proportional hazards regression models.
      </p>
      <h4>Data and safety monitoring</h4>
      <p style="line-height:160%">An independent Data Safety and Monitoring Committee (DSMC) comprising of experts in
         clinical trials, biostatistics and intensive care, will monitor SAEs throughout the
         trial, and pre-defined outcomes at designated interim analyses.
      </p>
      <p style="line-height:160%">Given the potential for EPO to increase the risk of VTE, there are two planned interim
         safety analyses scheduled by the DSMC at six months, following 33% (n = 202) and 66%
         (n = 404) patient recruitment. The Haybittle-Peto criterion (|Z<sub>k</sub>| &gt; =3) for early stopping were applied at these first and second analyses. The final
         analyses at full recruitment will be little affected by these interim analyses (final
         critical value |Z<sub>3</sub>| &gt; =1.975 rather than 1.960) <a name="d75303e740"></a>[<a onclick="LoadInParent('#B33'); return false;" href="#B33">33</a>].
      </p>
      <p style="line-height:160%">Consistent with other studies in critically ill patients, AEs already defined and
         reported as study outcomes (apart from death) will not be reported a second time as
         SAEs <a name="d75303e746"></a>[<a onclick="LoadInParent('#B34'); return false;" href="#B34">34</a>].
      </p>
   </div>
</section>
<section><a name="sec3"></a><h3>Discussion</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">TBI is a common and devastating condition with few proven specific therapies available.
         The administration of EPO has the potential to reduce neurological damage and improve
         outcome, and is supported by a scientific rationale and laboratory data. The EPO-TBI
         design aims to maximise the ability to detect a beneficial effect, if one exists,
         between EPO and improved neurological function after TBI. Furthermore, our design
         features also aim to minimise the risk of VTE in this population, and to develop a
         prospective screening plan which will readily identify VTE events if they occur, allowing
         clinicians to provide appropriate treatment rapidly. EPO-TBI aims to provide definitive
         guidance for clinicians regarding the true efficacy and safety of EPO in the management
         of TBI.
      </p>
      <h4>Trial status</h4>
      <p style="line-height:160%">The trial commenced in May 2010 at The Alfred Hospital, Melbourne Australia. Two interim
         analyses were conducted with approval by the DSMC to continue the trial without alteration
         to the protocol. The target recruitment of 606 patients was achieved on 1 November
         2014, making final six-month outcomes available by May 2015.
      </p>
   </div>
</section>
<section><a name="sec4"></a><h3>Endnotes</h3>
   <div class="collapsible-content">
      <p style="line-height:160%"><sup>a</sup>Six sites have a minimum age of 15 years, 13 sites have a minimum age of 16 years
         and 10 sites have a minimum age of 18 years.
      </p>
      <p style="line-height:160%"><sup>b</sup>&lt;140 g/L at Johannes Gutenberg-Universtität, Mainz Germany, &lt;148 g/L for males and
         &lt;135 g/L for females at Royal Adelaide Hospital, Adelaide Australia.
      </p>
      <p style="line-height:160%"><sup>c</sup>Additional exclusion criteria at Johannes Gutenberg-Universtität, Mainz Germany. Uncontrolled
         hypertension parameters were more stringent (systolic blood pressure of &gt;160 mm Hg
         or diastolic blood pressure of &gt;90 mm Hg), morbid obesity, coronary artery disease,
         peripheral arterial occlusive disease, vascular disease of the carotid arteries, cerebrovascular
         disorders, recent stroke, contraindications against prophylaxis of DVT or an increased
         risk for DVT (for example, with additional trauma and /or operations, severe varicose
         veins, severe smokers, intake of oral contraceptives, infections and inflammation).
      </p>
   </div>
</section>
<section><a name="sec5"></a><h3>Abbreviations</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">AE: Adverse event</p>
      <p style="line-height:160%">AIS: Abbreviated injury severity score</p>
      <p style="line-height:160%">ANZIC-RC: Australian and New Zealand Intensive Care Research Centre</p>
      <p style="line-height:160%">APACHE II: Acute Physiology and Chronic Health Evaluation II</p>
      <p style="line-height:160%">CI: Confidence interval</p>
      <p style="line-height:160%">DSMC: Data and Safety Monitoring Committee</p>
      <p style="line-height:160%">DVT: Deep venous thrombosis</p>
      <p style="line-height:160%">EPO: Erythropoietin</p>
      <p style="line-height:160%">EPO-TBI: Erythropoietin in Traumatic Brain Injury</p>
      <p style="line-height:160%">EQ-5D: EuroQol five dimensions</p>
      <p style="line-height:160%">GCS: Glasgow coma score</p>
      <p style="line-height:160%">GOSE: Extended Glasgow outcome scale</p>
      <p style="line-height:160%">Hb: Haemoglobin</p>
      <p style="line-height:160%">ISS: Injury severity score</p>
      <p style="line-height:160%">SF-12: Short Form-12</p>
      <p style="line-height:160%">TBI: Traumatic brain injury</p>
      <p style="line-height:160%">VTE: Venous thromboembolism</p>
   </div>
</section>
<section><a name="sec6"></a><h3>Competing interests</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The authors declare that they have no competing interests.</p>
   </div>
</section>
<section><a name="sec7"></a><h3>Authors’ contributions</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">AN contributed to the original concept of the trial, contributed to acquisition of
         funding and drafted the manuscript; CF contributed to the original concept of the
         trial, drafted the manuscript and administration; LL manages the trial, contributed
         to the drafting of the manuscript and administration; JP drafted the statistical analysis
         component of the manuscript, contributed to the drafting of the manuscript and administration;
         DJC contributed to the original concept of the trial, acquired funding for the trial
         and contributed to the statistical analysis plan; SH is the principal investigator
         of the highest recruiting site, made significant contribution to the setup of the
         trial in the Kingdom of Saudi Arabia and contributed to the drafting of the manuscript;
         JD is the national principal investigator for France and contributed to the drafting
         of the manuscript; OH made a significant contribution to the setup of the trial in
         France and contributed to the drafting of the manuscript; MS contributed to the drafting
         of the manuscript and made a significant contribution to the setup of the trial in
         Finland; YA contributed to the drafting of the manuscript and is sub-investigator
         at the highest recruiting site; RB contributed to the original concept of the trial,
         was the leader in acquisition of funding and is the chief investigator. All authors
         read and approved the final manuscript.
      </p>
   </div>
</section>
<section><a name="sec8"></a><h3>Appendix 1: EPO-TBI unblinded project officer</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Belinda Howe, Australian and New Zealand Intensive Care Research Centre, Monash University,
         Melbourne, Australia.
      </p>
   </div>
</section>
<section><a name="sec9"></a><h3>Appendix 2: EPO-TBI outcome assessors</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Heather Waddy, Australian and New Zealand Intensive Care Research Centre, Monash University,
         Melbourne, Australia.
      </p>
      <p style="line-height:160%">Marwan Al Kishi, Department of Medicine, King Abdulaziz Medical City, Riyadh, Kingdom
         of Saudi Arabia.
      </p>
      <p style="line-height:160%">Sarah Kambire, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
         de Paris, France.
      </p>
      <p style="line-height:160%">Serge Camelo, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
         de Paris, France.
      </p>
      <p style="line-height:160%">Markus Skrifvars, Intensive Care Unit, Department of Anaesthesiology and Intensive
         Care Medicine, Helsinki University Hospital, Helsinki, Finland.
      </p>
      <p style="line-height:160%">Stepani Bendel, Intensive Care Unit, Division of Anaesthesiology and Intensive Care
         Medicine, Kuopio University Hospital, Kuopio, Finland.
      </p>
      <p style="line-height:160%">Carole Schilling, Royal College of Surgeons in Ireland, Education and Research Centre,
         Beaumont Hospital, Dublin, Ireland.
      </p>
      <p style="line-height:160%">Thomas Kerz, Department of Neurosurgery, Intensive Care Therapy Unit, Universitätsmedizin,
         Mainz, Germany.
      </p>
      <p style="line-height:160%">Lynnette Murray, Australian and New Zealand Intensive Care Research Centre, Monash
         University, Melbourne, Australia.
      </p>
   </div>
</section>
<section><a name="sec10"></a><h3>Appendix 3: EPO-TBI management committee</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Rinaldo Bellomo, Department of Intensive Care, Austin Health, Melbourne, Australia.</p>
      <p style="line-height:160%">Alistair Nichol, Department of Anaesthesia and Intensive Care Medicine, St Vincent’s
         University Hospital, Dublin, Ireland.
      </p>
      <p style="line-height:160%">Craig French, Department of Intensive Care, Western Health, Melbourne, Australia.</p>
      <p style="line-height:160%">D James Cooper, Department of Intensive Care Medicine, The Alfred, Melbourne, Australia.</p>
      <p style="line-height:160%">Olivier Huet, Intensive Care Unit, Department of Anesthesiology and Intensive Care
         Medicine, Centre Hospitalier Universitaire La Cavale Blanche, Brest, France.
      </p>
      <p style="line-height:160%">Lorraine Little, Australian and New Zealand Intensive Care Research Centre, Monash
         University, Melbourne, Australia.
      </p>
      <p style="line-height:160%">Anne Mak, Pharmacy Department, The Alfred, Melbourne, Australia.</p>
      <p style="line-height:160%">Ville Pettilä, Intensive care Units, Division of Anaesthesiology and Intensive Care
         Medicine, Helsinki University Central Hospital, Helsinki, Finland.
      </p>
      <p style="line-height:160%">Jeffrey Presneill, Department of Intensive Care, Mater Health Services, Brisbane,
         Australia.
      </p>
      <p style="line-height:160%">Shirley Vallance, Department of Intensive Care Medicine, The Alfred, Melbourne, Australia.</p>
      <p style="line-height:160%">Dinesh Varma, Department of Radiology, The Alfred, Melbourne, Australia.</p>
      <p style="line-height:160%">Judy Wills, Department of Radiology, The Alfred, Melbourne, Australia.</p>
   </div>
</section>
<section><a name="sec11"></a><h3>Appendix 4: EPO-TBI sites, principal investigator and research coordinator/s</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Auckland City Hospital, New Zealand: Colin McArthur, Yan Chen, Lynette Newby.</p>
      <p style="line-height:160%">Beaumont Hospital, Ireland: Criona Walshe, James O’Rourke, Carole Schilling.</p>
      <p style="line-height:160%">Canberra Hospital, Australia: Imogen Mitchell, Frank Van Haren, Helen Rodgers. Marta
         Kot
      </p>
      <p style="line-height:160%">Christchurch Hospital, New Zealand: Seton Henderson, Jan Mehrtens, Sascha Noble.</p>
      <p style="line-height:160%">Dunedin Hospital, New Zealand: Matthew Bailey, Robyn Hutchinson, Dawn France.</p>
      <p style="line-height:160%">Gold Coast University Hospital, Australia: Brent Richards, Mandy Tallott.</p>
      <p style="line-height:160%">Helsinki University Central Hospital, Finland: Markus Skrifvars, Heikki Vartiala,
         Marianne Eliasson.
      </p>
      <p style="line-height:160%">Hôpital Caremeau, France: Jean Yves Lefrant, Laurent Muller, Claire Roger, Christian
         Bengler, Pierre Barbaste.
      </p>
      <p style="line-height:160%">Hôpital Charles Nicolle, France: Benoit Veber, Marie Gilles-Baray, Pierre-Gildas Guitard,
         Helene Braud.
      </p>
      <p style="line-height:160%">Hôpital de Bicêtre, France: Jacques Duranteau, Anatole Harrois, Samy Figueiredo, Sophie
         Hamada.
      </p>
      <p style="line-height:160%">Hôpital Lariboisière, France: Didier Payen, Anne Claire Lukaszewicz, Charles Damoisel,
         Sarah Kambire.
      </p>
      <p style="line-height:160%">Hôpital Michallon, France: Jean François Payen, Pauline Manhes, Gilles Franconey,
         Perrine Boucheix.
      </p>
      <p style="line-height:160%">Johannes Gutenberg-Universtität, Germany: Thomas Kerz.</p>
      <p style="line-height:160%">John Hunter Hospital, Australia: Peter Harrigan, Miranda Hardie.</p>
      <p style="line-height:160%">King Abdulaziz Medical City, Kingdom of Saudi Arabia: Samir Haddad, Yaseen Arabi,
         Marwan Al Kishi, Ahmad Deeb, Shmeylan Al Harbi, Lolowa Al-Swaidan ,Turki Al Moammar,
         Juliet Lingling, Shella Caliwag, Hanie Richi.
      </p>
      <p style="line-height:160%">Kuopio University Hospital, Finland: Stepani Bendel, Sari Rahikainen, Mikko Myllymaki.</p>
      <p style="line-height:160%">Liverpool Hospital, Australia: Victor Tam, Sharon Micallef.</p>
      <p style="line-height:160%">Nepean Hospital, Australia: Louise Cole, Leonie Weisbrodt.</p>
      <p style="line-height:160%">Royal Adelaide Hospital, Australia: Richard Strickland, Justine Rivett, Sonya Kloeden,
         Stephanie O’Connor.
      </p>
      <p style="line-height:160%">Royal Hobart Hospital, Australia: David Cooper, Richard McAllister.</p>
      <p style="line-height:160%">Royal Melbourne Hospital, Australia: Nerina Harley, Deborah Barge, Elizabeth Moore,
         Andrea Jordan.
      </p>
      <p style="line-height:160%">Royal North Shore Hospital, Australia: Simon Finfer, Elizabeth Yarad, Simon Bird,
         Anne O’Connor.
      </p>
      <p style="line-height:160%">Royal Perth Hospital, Australia: Geoffrey Dobb, Jenny Chamberlain, Michelle Barr,
         Elizabeth Jenkinson.
      </p>
      <p style="line-height:160%">Royal Prince Alfred Hospital, Australia: David Gattas, Heidi Buhr, Debra Hutch, Megan
         Keir.
      </p>
      <p style="line-height:160%">St Vincent’s Hospital Sydney, Australia: Priya Nair, Claire Reynolds, Serena Knowles.</p>
      <p style="line-height:160%">The Alfred, Australia: D. James Cooper, Jasmin Board, Shirley Vallance, Phoebe McCracken.</p>
      <p style="line-height:160%">The Townsville Hospital, Australia: Geoffrey Gordon, Stephen Reeves.</p>
      <p style="line-height:160%">Wellington Regional Hospital, New Zealand: Richard Dinsdale, Lynn Andrews, Dianne
         Mackle, Sally Hurford.
      </p>
      <p style="line-height:160%">Westmead Hospital, Australia: Vineet Nayyar, Christina Whitehead, Jing Kong.</p>
   </div>
</section>
<section><a name="sec12"></a><h3>Appendix 5: EPO-TBI French management team</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Jacques Duranteau, National Principal Investigator, Service d’Anesthésie-Réanimation,
         Hôpitaux universitaires Paris Sud, Assistance Publique des Hôpitaux de Paris, Hôpital
         de Bicêtre, Le Kremlin-Bicêtre, France.
      </p>
      <p style="line-height:160%">Eric Vicaut, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
         de Paris, France.
      </p>
      <p style="line-height:160%">Philippe Gallula, Pole Promotion International, Assistance Publique-Hôpitaux de Paris,
         France.
      </p>
      <p style="line-height:160%">Vidhya Raghavan, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance
         Publique-Hôpitaux de Paris, France.
      </p>
      <p style="line-height:160%">Amel Chamam, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
         de Paris, France.
      </p>
      <p style="line-height:160%">Sarah Kambire, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
         de Paris, France.
      </p>
   </div>
</section>
<section><a name="sec13"></a><h3>Additional file</h3>
   <div class="collapsible-content"><div class="figs">
      <div class="addfile"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/39/suppl/S1','S1',630,470); return false;" href="http://www.trialsjournal.com/content/16/1/39/suppl/S1"></a><strong>Additional file 1:.</strong> <strong>Project Title: Erythropoietin in traumatic brain injury.</strong> List of participating centres and responsible ethics committees.</p><p>
         	Format: PDF 
         	Size: 317KB <a href="/content/supplementary/s13063-014-0528-6-s1.pdf">Download file</a></p><p>This file can be viewed with: <a onclick="largepopup('http://www.adobe.com/products/acrobat/readstep.html','Help');return false;" href="http://www.adobe.com/products/acrobat/readstep.html">Adobe Acrobat Reader</a><span class="open-data-icon"><a href="/about/access/#opendata"><img title="Open Data" alt="Open Data" src="/bmcimages/article/opendata.gif"></a></span></div></div>
   </div>
</section>
<section><a name="ack"></a><h3>Acknowledgements</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">EPO-TBI is funded by the Australian National Health and Medical Research Council Project
         (project grant ID 545901), and the Victorian Transport Accident Commission (project
         grant ID D162 - formerly, the Victorian Neurotrauma Initiative). The cost of Epoetin
         alfa was reimbursed to hospital pharmacy departments by using project grant funds.
         Neither funding agencies nor the manufacturer of Epoetin alfa had any role in the
         trial design, data collection or analysis.
      </p>
      <p style="line-height:160%">EPO-TBI trial is coordinated by the Australian and New Zealand Intensive Care Research
         Centre (ANZIC-RC), Monash University, Melbourne, Australia and endorsed by the Australian
         and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) and the
         Irish Critical Care Trials Group. The members of Management Committee are listed in
         Appendix 3
         
      </p>
      <p style="line-height:160%">The EPO-TBI trial sites, principal investigator(s) and research coordinator(s) are
         listed in Appendix 4.
      </p>
      <p style="line-height:160%">EPO-TBI is managed in France by the Unité de Recherche Clinique Lariboisière-Saint
         Louis, Assistance Publique-Hôpitaux de Paris. The EPO-TBI French management team is
         listed in Appendix 5.
      </p>
   </div>
</section>
<section><a name="refs"></a><h3>References</h3>
   <div id="article-references" class="collapsible-content">
      <ol id="references">
         <li id="B1">
            <p><a name="B1"></a>Access Economics. The economic cost of spinal cord injury and traumatic brain injury
               in Australia. Report by Access Economics Pty Limited for The Victorian Neurotrauma
               Initiative. 2009; last access date 28 Jan 2015. http://www.tac.vic.gov.au/about-the-tac/our-organisation/research/tac-neurotrauma-research/vni/the20economic20cost20of20spinal20cord20injury20and20traumatic20brain20injury20in20australia.pdf.
            </p>
         </li>
         <li id="B2">
            <p><a name="B2"></a> Bramlett HM,  Dietrich WD: <strong> Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. </strong><p><em>J Cereb Blood Flow Metab</em> 2004,  <strong>24</strong><strong>:</strong>133-50.  <a target="_blank" href="/pubmed/14747740">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=14747740">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B2" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B2','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B3">
            <p><a name="B3"></a> Lykissas MG,  Korompilias AV,  Vekris MD,  Mitsionis GI,  Sakellariou E,  Beris AE: <strong> The role of erythropoietin in central and peripheral nerve injury. </strong><p><em>Clin Neurol Neurosurg</em> 2007,  <strong>109</strong><strong>:</strong>639-44.  <a target="_blank" href="/pubmed/17624659">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17624659">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B3" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B3','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B4">
            <p><a name="B4"></a> Coleman T,  Brines M: <strong> Science review: recombinant human erythropoietin in critical illness: a role beyond
                  anemia? </strong><p><em>Crit Care</em> 2004,  <strong>8</strong><strong>:</strong>337-41.  <a target="_blank" href="/pubmed/15469595">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/cc2897">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B4" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B4','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B5">
            <p><a name="B5"></a> Yatsiv I,  Grigoriadis N,  Simeonidou C,  Stahel PF,  Schmidt OI,  Alexandrovitch AG, <em>et al</em>.: <strong> Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal
                  apoptosis and inflammation in a rodent model of experimental closed head injury. </strong><p><em>FASEB J</em> 2005,  <strong>19</strong><strong>:</strong>1701-3.  <a target="_blank" href="/pubmed/16099948">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=16099948">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B5" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B5','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B6">
            <p><a name="B6"></a> Lu D,  Mahmood A,  Qu C,  Goussev A,  Schallert T,  Chopp M: <strong> Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic
                  brain injury. </strong><p><em>J Neurotrauma</em> 2005,  <strong>22</strong><strong>:</strong>1011-7.  <a target="_blank" href="/pubmed/16156716">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=16156716">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B6" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B6','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B7">
            <p><a name="B7"></a> Corwin HL,  Gettinger A,  Pearl RG,  Fink MP,  Levy MM,  Shapiro MJ, <em>et al</em>.: <strong> Efficacy of recombinant human erythropoietin in critically ill patients: a randomized
                  controlled trial. </strong><p><em>JAMA</em> 2002,  <strong>288</strong><strong>:</strong>2827-35.  <a target="_blank" href="/pubmed/12472324">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=12472324">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B7" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B7','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B8">
            <p><a name="B8"></a> Corwin HL,  Gettinger A,  Fabian TC,  May A,  Pearl RG,  Heard S, <em>et al</em>.: <strong> Efficacy and safety of epoetin alfa in critically ill patients. </strong><p><em>N Engl J Med</em> 2007,  <strong>357</strong><strong>:</strong>965-76.  <a target="_blank" href="/pubmed/17804841">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17804841">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B8" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B8','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B9">
            <p><a name="B9"></a> Abrishamkar S,  Safavi M,  Honarmand A: <strong> Effect of erythropoietin on Glasgow Coma Scale and Glasgow Outcome Sale in patient
                  with diffuse axonal injury. </strong><p><em>J Res Med Sci</em> 2012,  <strong>17</strong><strong>:</strong>51-6.  <a target="_blank" href="/pubmed/23248657">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23248657">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B9" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B9','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B10">
            <p><a name="B10"></a> Talving P,  Lustenberger T,  Inaba K,  Lam L,  Mohseni S,  Chan L, <em>et al</em>.: <strong> Erythropoiesis-stimulating agent administration and survival after severe traumatic
                  brain injury: a prospective study. </strong><p><em>Arch Surg</em> 2012,  <strong>147</strong><strong>:</strong>251-5.  <a target="_blank" href="/pubmed/22430906">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22430906">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B10" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B10','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B11">
            <p><a name="B11"></a> Tonia T,  Mettler A,  Robert N,  Schwarzer G,  Seidenfeld J,  Weingart O, <em>et al</em>.: <strong> Erythropoietin or darbepoetin for patients with cancer. </strong><p><em>Cochrane Database Syst Rev</em> 2012,  <strong>12</strong><strong>:</strong>CD003407.  <a target="_blank" href="/pubmed/23235597">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23235597">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B11" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B11','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B12">
            <p><a name="B12"></a> Singh AK,  Szczech L,  Tang KL,  Barnhart H,  Sapp S,  Wolfson M, <em>et al</em>.: <strong> Correction of anemia with epoetin alfa in chronic kidney disease. </strong><p><em>N Engl J Med</em> 2006,  <strong>355</strong><strong>:</strong>2085-98.  <a target="_blank" href="/pubmed/17108343">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17108343">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B12" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B12','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B13">
            <p><a name="B13"></a> Teasdale GM,  Pettigrew LE,  Wilson JT,  Murray G,  Jennett B: <strong> Analyzing outcome of treatment of severe head injury: a review and update on advancing
                  the use of the Glasgow Outcome Scale. </strong><p><em>J Neurotrauma</em> 1998,  <strong>15</strong><strong>:</strong>587-97.  <a target="_blank" href="/pubmed/9726258">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=9726258">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B13" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B13','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B14">
            <p><a name="B14"></a> Ware J Jr,  Kosinski M,  Keller SD: <strong> A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of
                  reliability and validity. </strong><p><em>Med Care</em> 1996,  <strong>34</strong><strong>:</strong>220-33.  <a target="_blank" href="/pubmed/8628042">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=8628042">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B14" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B14','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B15">
            <p><a name="B15"></a>EuroQol Group. EQ-5D™ instrument for describing and valuing health-related quality
               of life. 2014. Last access date 28 Jan 2015. http://www.euroqol.org/home.html.
            </p>
         </li>
         <li id="B16">
            <p><a name="B16"></a> Cook DJ,  Rocker G,  Meade M,  Guyatt G,  Geerts W,  Anderson D, <em>et al</em>.: <strong> Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. </strong><p><em>J Crit Care</em> 2005,  <strong>20</strong><strong>:</strong>364-72.  <a target="_blank" href="/pubmed/16310609">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=16310609">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B16" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B16','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B17">
            <p><a name="B17"></a> Vincent JL,  Baron JF,  Reinhart K,  Gattinoni L,  Thijs L,  Webb A, <em>et al</em>.: <strong> Anemia and blood transfusion in critically ill patients. </strong><p><em>JAMA</em> 2002,  <strong>288</strong><strong>:</strong>1499-507.  <a target="_blank" href="/pubmed/12243637">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=12243637">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B17" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B17','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B18">
            <p><a name="B18"></a> Corwin HL,  Gettinger A,  Pearl RG,  Fink MP,  Levy MM,  Abraham E, <em>et al</em>.: <strong> The CRIT Study: anemia and blood transfusion in the critically ill - current clinical
                  practice in the United States. </strong><p><em>Crit Care Med</em> 2004,  <strong>32</strong><strong>:</strong>39-52.  <a target="_blank" href="/pubmed/14707558">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=14707558">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B18" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B18','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B19">
            <p><a name="B19"></a>Brain Trauma Foundation: 
               	<strong> Guidelines for the management of severe traumatic brain injury </strong><p><em>J Neurotrauma</em> 2007,  <strong>24</strong>(Suppl 1)<strong>:</strong>S1-106.  <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B19" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B19','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B20">
            <p><a name="B20"></a> Marshall LF,  Marshall SB,  Klauber MR,  Van Berkum CM,  Eisenberg H,  Jane JA, <em>et al</em>.: <strong> The diagnosis of head injury requires a classification based on computed axial tomography. </strong><p><em>J Neurotrauma</em> 1992,  <strong>9</strong>(Suppl 1)<strong>:</strong>S287-92.  <a target="_blank" href="/pubmed/1588618">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=1588618">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B20" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B20','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B21">
            <p><a name="B21"></a> Wilson JT,  Pettigrew LE,  Teasdale GM: <strong> Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome
                  Scale: guidelines for their use. </strong><p><em>J Neurotrauma</em> 1998,  <strong>15</strong><strong>:</strong>573-85.  <a target="_blank" href="/pubmed/9726257">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=9726257">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B21" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B21','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B22">
            <p><a name="B22"></a> Fergusson D,  Aaron SD,  Guyatt G,  Hebert P: <strong> Post-randomisation exclusions: the intention to treat principle and excluding patients
                  from analysis. </strong><p><em>BMJ</em> 2002,  <strong>325</strong><strong>:</strong>652-4.  <a target="_blank" href="/pubmed/12242181">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=12242181">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B22" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B22','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B23">
            <p><a name="B23"></a> Perner A,  Haase N,  Guttormsen AB,  Tenhunen J,  Klemenzson G,  Aneman A, <em>et al</em>.: <strong> Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. </strong><p><em>N Engl J Med</em> 2012,  <strong>367</strong><strong>:</strong>124-34.  <a target="_blank" href="/pubmed/22738085">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22738085">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B23" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B23','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B24">
            <p><a name="B24"></a> Dijkers MP: <strong> Quality of life after traumatic brain injury: a review of research approaches and
                  findings. </strong><p><em>Arch Phys Med Rehabil</em> 2004,  <strong>85</strong><strong>:</strong>S21-35.  <a target="_blank" href="/pubmed/15083419">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15083419">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B24" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B24','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B25">
            <p><a name="B25"></a> Bullinger M,  Azouvi P,  Brooks N,  Basso A,  Christensen AL,  Gobiet W, <em>et al</em>.: <strong> Quality of life in patients with traumatic brain injury-basic issues, assessment and
                  recommendations. </strong><p><em>Restor Neurol Neurosci</em> 2002,  <strong>20</strong><strong>:</strong>111-24.  <a target="_blank" href="/pubmed/12454360">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=12454360">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B25" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B25','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B26">
            <p><a name="B26"></a> Myburgh JA,  Cooper DJ,  Finfer SR,  Venkatesh B,  Jones D,  Higgins A, <em>et al</em>.: <strong> Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New
                  Zealand. </strong><p><em>J Trauma</em> 2008,  <strong>64</strong><strong>:</strong>854-62.  <a target="_blank" href="/pubmed/18404048">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18404048">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B26" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B26','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B27">
            <p><a name="B27"></a> Myburgh J,  Cooper DJ,  Finfer S,  Bellomo R,  Norton R,  Bishop N, <em>et al</em>.: <strong> Saline or albumin for fluid resuscitation in patients with traumatic brain injury. </strong><p><em>N Engl J Med</em> 2007,  <strong>357</strong><strong>:</strong>874-84.  <a target="_blank" href="/pubmed/17761591">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17761591">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B27" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B27','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B28">
            <p><a name="B28"></a> Hosmer DW,  Lemeshow S,  Sturdivant RX: <em>Applied logistic regression</em>.  Wiley, Hoboken, New Jersey;  2013. <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B28" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B28','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B29">
            <p><a name="B29"></a> Roozenbeek B,  Lingsma HF,  Perel P,  Edwards P,  Roberts I,  Murray GD, <em>et al</em>.: <strong> The added value of ordinal analysis in clinical trials: an example in traumatic brain
                  injury. </strong><p><em>Crit Care</em> 2011,  <strong>15</strong><strong>:</strong>R127.  <a target="_blank" href="/pubmed/21586148">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/cc10240">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B29" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B29','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B30">
            <p><a name="B30"></a>Cummings P. Re: converting an adjusted odds ratio to a risk ratio will produce biased
               estimates. BMJ. 2014; 348:f7450/rr/684808.
            </p>
         </li>
         <li id="B31">
            <p><a name="B31"></a> Grant RL: <strong> Converting an odds ratio to a range of plausible relative risks for better communication
                  of research findings. </strong><p><em>BMJ</em> 2014,  <strong>348</strong><strong>:</strong>f7450.  <a target="_blank" href="/pubmed/24464277">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=24464277">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B31" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B31','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B32">
            <p><a name="B32"></a> Norton EC,  Miller MM,  Kleinman LC: <strong> Computing adjusted risk ratios and risk differences in Stata. </strong><p><em>Stata J</em> 2013,  <strong>13</strong><strong>:</strong>492-509.  <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B32" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B32','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B33">
            <p><a name="B33"></a> Jennison C,  Turnbull BW: <em>Group sequential methods with applications to clinical trials</em>.  Chapman &amp; Hall/CRC, Boca Raton, Florida;  2000. <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B33" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B33','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B34">
            <p><a name="B34"></a> Cook D,  Lauzier F,  Rocha MG,  Sayles MJ,  Finfer S: <strong> Serious adverse events in academic critical care research. </strong><p><em>CMAJ</em> 2008,  <strong>178</strong><strong>:</strong>1181-4.  <a target="_blank" href="/pubmed/18427095">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18427095">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-014-0528-6&amp;bibl=B34" onclick="popup('/sfx_links?ui=s13063-014-0528-6&amp;bibl=B34','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
      </ol>
   </div>
</section>
    <br class="clearall">
<div class="article-alert-signup-div">

<a class="close png_bg" id="closeHelpBox" >close</a>	
<div class="article-alert-signup rounded" > 
<span class="blurb left">Sign up to receive new article alerts from <em>Trials</em></span>

	
				<button name="articleAlertPreference.status" type="button" class="w74 right" onClick="window.location='/my/preferences'">Sign up</button>
	
</div>
</div></div>
    </div></div>
</div>


		</div>
</div>

    <hr class="hide" />
	
    

						
   
  
      
  
                  
  
                  
  
            
  
            
            


<div id="footer">

						
			<span class="views"><a id="mobile-view" href="?fmt_view=mobile">Mobile view</a> | <strong>Desktop view</strong></span>
			
	<div class="content">
    <div class="rounded ">
<div class="wrap-inner ">
        	
    <ul class="desktop">
                                                    
				        <li class="noborder"><a href="http://www.biomedcentral.com/about/tandc">Terms and Conditions</a></li>
<li><a href="http://www.biomedcentral.com/about/privacy">Privacy statement</a></li>
<li><a href="http://www.biomedcentral.com/presscenter">Press</a></li>
	<li><a href="http://www.biomedcentral.com/advertisers">Information for advertisers</a></li>
<li><a href="http://www.biomedcentral.com/about/bmcjobs">Jobs at BMC</a></li>
<li><a href="/support">Support</a></li>
<li><a href="/about/contact">Contact us</a></li>


    
    	    </ul>
    <p id="copyright">&copy; 2015 
	BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business&nbsp;Media.</p>
        </div>
</div>

	</div>

</div>
<div class="springer">
    <a href="http://www.springer.com/" target="blank"><img style="float:right; margin:0;" src="
    //www.biomedcentral.com/images/Springer_Branding_footer_logo.png" /></a>
</div>


<script>window.bmcIsMobile = "classic";</script>					    

<script>
// getElementsByClassName Polyfill
var getElementsByClassName=function(e,t,n){if(document.getElementsByClassName){getElementsByClassName=function(e,t,n){n=n||document;var r=n.getElementsByClassName(e),i=t?new RegExp("\\b"+t+"\\b","i"):null,s=[],o;for(var u=0,a=r.length;u<a;u+=1){o=r[u];if(!i||i.test(o.nodeName)){s.push(o)}}return s}}else if(document.evaluate){getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i="",s="http://www.w3.org/1999/xhtml",o=document.documentElement.namespaceURI===s?s:null,u=[],a,f;for(var l=0,c=r.length;l<c;l+=1){i+="[contains(concat(' ', @class, ' '), ' "+r[l]+" ')]"}try{a=document.evaluate(".//"+t+i,n,o,0,null)}catch(h){a=document.evaluate(".//"+t+i,n,null,0,null)}while(f=a.iterateNext()){u.push(f)}return u}}else{getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i=[],s=t==="*"&&n.all?n.all:n.getElementsByTagName(t),o,u=[],a;for(var f=0,l=r.length;f<l;f+=1){i.push(new RegExp("(^|\\s)"+r[f]+"(\\s|$)"))}for(var c=0,h=s.length;c<h;c+=1){o=s[c];a=false;for(var p=0,d=i.length;p<d;p+=1){a=i[p].test(o.className);if(!a){break}}if(a){u.push(o)}}return u}}return getElementsByClassName(e,t,n)}
</script>

						



<script type="text/javascript">
if (typeof jQuery == 'undefined') { document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.min.js' type='text/javascript'%3E%3C/script%3E")); }


document.documentElement.id = "js";

var site = {
			abbreviation: "",
	        type: "BMC_NICHE",
        portalId: "9001",
                section: "browse",
                page: "fulltext",
    		
									homePortal: "biomedcentral.com",
		
			siteShowAds: "true",
				showAds: "true",
				url: "trialsjournal.com",
			portal: false,
	        adpage_url: "trialsjournal.com/article/10.1186/s13063/014/0528/6",
        id: "10096",
	name: "Trials",
	plugins: {
		scrollable: (getElementsByClassName("scrollable").length > 0),
				flowplayer: ((document.getElementById("flowplayer") != null) || (getElementsByClassName("myPlayer").length > 0) || (document.getElementById("videoarticle") != null) || (getElementsByClassName("flowplayer").length > 0) || (document.getElementById("audio") != null) || (document.getElementById("elifeplayer") != null)),
		lightbox: ((document.getElementById("image-highlight") != null) || (getElementsByClassName("lightbox").length > 0)),
		thickbox: (getElementsByClassName("thickbox").length > 0),
		altmetric: ((document.getElementById("altmetric") != null) || (getElementsByClassName("altmetric").length > 0))
	}
	
};



if(typeof quoteSearchUri == "undefined") { quoteSearchUri=null; }
</script>



        <script type="text/javascript" src="http://www.bmcimg.com/javascript/journals/behaviours-0.js"></script>






		<script>
	if (site.plugins.scrollable == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.scrollable-1.0.1.min.js' %3E%3C/script%3E")); 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.tools.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.flowplayer == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/flowplayer-3.2.6.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.lightbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/browse_imagehighlight.js'%3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.colorbox.js' %3E%3C/script%3E"));
	}

	if (site.plugins.thickbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-compressed.js' %3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-flashhidden-patch.js' %3E%3C/script%3E"));
	}
	</script>





            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.fancybox-1.3.1.pack-0.js"></script>
            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.debug-0.js"></script>
                      <script type="text/javascript" src="http://www.bmcimg.com/javascript/email_preferences/email_preferences-0.js"></script>
                <script type="text/javascript" src="http://www.bmcimg.com/javascript/articles/articles-0.js"></script>
		<div id="fb-root"></div>











        <script type="text/javascript" src="/javascript/plugins/jquery.tagcloud.min-0.js"></script>




<!--[if lte IE 6]>
            <script type="text/javascript" src="/javascript/plugins/DD_belatedPNG_0.0.8a-0.js"></script>
    <script type="text/javascript">
        DD_belatedPNG.fix('.png_bg, ul.primary-nav li a, ul.primary-nav li a span, ul.secondary-nav li a, ul.secondary-nav li a span, ul li i, .plus-button, .facebook, .twitter, .fancy-bg, #fancybox-close');
    </script>
	                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/hacks/ie6-0.css"/>
    <![endif]-->

<!-- Claudia Whitcombe wanted this comment here -->

       <div class="hide">
      <dl class="google-ad" id="x96banner">
        <dt style="display: block;" class="hide">
          <a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
       </dt>
        <dd>
          <!-- OAS AD 'x96' begin -->
          <script type="text/javascript">
            OAS_AD('x96');
          </script>
        </dd>
      </dl>
    </div>  
    
</body>
</html>

